<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Virol J</journal-id><journal-id journal-id-type="iso-abbrev">Virol. J</journal-id><journal-title-group><journal-title>Virology Journal</journal-title></journal-title-group><issn pub-type="epub">1743-422X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4673751</article-id><article-id pub-id-type="publisher-id">444</article-id><article-id pub-id-type="doi">10.1186/s12985-015-0444-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Tackling dengue fever: Current status and challenges</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nedjadi</surname><given-names>Taoufik</given-names></name><address><phone>+966591417042</phone><email>tnedjadi@kau.edu.sa</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>El-Kafrawy</surname><given-names>Sherif</given-names></name><address><email>saelkfrawy@kau.edu.sa</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Sohrab</surname><given-names>Sayed S.</given-names></name><address><email>ssohrab@kau.edu.sa</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Despr&#x000e8;s</surname><given-names>Philippe</given-names></name><address><email>philippe.despres@univ-reunion.fr</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Damanhouri</surname><given-names>Ghazi</given-names></name><address><email>gdamanhouri@kau.edu.sa</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Azhar</surname><given-names>Esam</given-names></name><address><email>eazhar@kau.edu.sa</email></address><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia </aff><aff id="Aff2"><label/>Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia </aff><aff id="Aff3"><label/>UMR PIMIT (I2T team), University of Reunion island, INSERM U1187, CNRS 9192, IRD 249, Technology Platform CYROI, 2 rue Maxime Rivi&#x000e8;re Saint-Clotilde, La Reunion, 97491 France </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>12</volume><elocation-id>212</elocation-id><history><date date-type="received"><day>12</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>1</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Nedjadi et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p>According to recent statistics, 96 million apparent dengue infections were estimated worldwide in 2010. This figure is by far greater than the WHO prediction which indicates the rapid spread of this disease posing a growing threat to the economy and a major challenge to clinicians and health care services across the globe particularly in the affected areas.</p><p>This article aims at bringing to light the current epidemiological and clinical status of the dengue fever. The relationship between genetic mutations, single nucleotide polymorphism (SNP) and the pathophysiology of disease progression will be put into perspective. It will also highlight the recent advances in dengue vaccine development.</p><p>Thus far, a significant progress has been made in unraveling the risk factors and understanding the molecular pathogenesis associated with the disease. However, further insights in molecular features of the disease and the development of animal models will enormously help improving the therapeutic interventions and potentially contribute to finding new preventive measures for population at risk.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Dengue</kwd><kwd><italic>Aedes Aegypti</italic></kwd><kwd>Dengue hemorrhagic fever</kwd><kwd>Hemorrhagic shock syndrome</kwd><kwd>Genetic susceptibility</kwd><kwd>Vaccine development</kwd></kwd-group><funding-group><award-group><funding-source><institution>King Abdulaziz City for Science and Technology</institution></funding-source><award-id>&#x00627;&#x0062a;&#x00627;&#x0062a;-33-26</award-id><principal-award-recipient><name><surname>Nedjadi</surname><given-names>Taoufik</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Dengue fever is a major cause of illness and death worldwide. The disease is caused by dengue virus which gets transmitted to humans by the bites of infected mosquitoes, <italic>Aedes (Ae.) aegypti</italic> and <italic>Ae. albopictus</italic> [<xref ref-type="bibr" rid="CR1">1</xref>]. The disease represents a global health issue as it is endemic in around 100 countries, most of which are in tropical and sub-tropical areas. Over the last decades, the incidence rate and the geographic distribution of dengue have rapidly increased (almost 30-fold). Data from the World Health Organization (WHO) estimates up to 100 million cases of dengue fever each year [<xref ref-type="bibr" rid="CR2">2</xref>]. However, a recent published work by Bhatt et al<italic>.</italic> (2013) suggested that the burden of dengue is far more than the WHO estimation and indicated that 390 million infections of dengue virus could have happened every year [<xref ref-type="bibr" rid="CR3">3</xref>]. Changes in dengue epidemiology and the increase in incidence rates (with and without co-morbidities) have led the WHO to propose a new dengue classification system according to disease severity (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR2">2</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>WHO dengue case classification (<italic>Adopted from; Dengue Guidelines for diagnosis, treatment, prevention and control, New edn. Geneva: WHO; 2009</italic>)</p></caption><graphic xlink:href="12985_2015_444_Fig1_HTML" id="MO1"/></fig></p><sec id="Sec2"><title>Etiology and mode of transmission</title><p>Dengue fever is caused by infection with dengue virus (DENV). The DENV is a vector-borne virus transmitted to humans primarily by bites from two mosquito species, <italic>Ae. aegypti</italic> or <italic>Ae. albopictus</italic>. DENV is a single positive-stranded RNA virus belonging to Flavivirus genus of the <italic>Flaviviridae</italic> family and has 4 major serotypes (DENV 1&#x02013;4) that are antigenically distinct from each other. Each DENV serotype is phylogenetically distinct suggesting that each serotype could be considered a separate virus [<xref ref-type="bibr" rid="CR4">4</xref>]. Three dengue serotypes out of four (DENV 1&#x02013;3) have been found in Middle Eastern countries including Saudi Arabia and Yemen. Interestingly, DENV-1 strain isolated in Saudi Arabia exhibited a high genetic similarity with DENV-1 strain isolated from Asian population, suggesting a widespread of the Asian genotype, probably through Asian pilgrims [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. A recently published article has unveiled a new serotype (DENV-5), to be added to the existing ones [<xref ref-type="bibr" rid="CR7">7</xref>]. This discovery is still controversial and little-known enough to conclude how the 5<sup>th</sup> dengue serotype might add to the burden associated with dengue infection.</p><p>Mosquitoes transmit the virus by feeding on blood of infected persons. At first, the virus infects and replicates in the mid-gut epithelium of the mosquito and then spreads to other organs until it reaches the salivary glands after 10&#x02013;14 days where it can be inoculated to another person during subsequent blood meal. Vertical transmission of DENV in mosquitoes, i.e. from mosquito to larvae has been reported by a number of research groups. In India, Angel &#x00026; Joshi (2008) reported the detection of dengue virus by indirect fluorescence antibody test (IFAT) in laboratory reared mosquitoes originating from larvae collected from urban and rural areas [<xref ref-type="bibr" rid="CR8">8</xref>]. A similar study was conducted in Brazil by Martins et al. (2012) and confirmed the isolation of DENV-type 3 in <italic>Ae. albopictus</italic> larvae and DENV-type 2 in <italic>Ae. aegypti</italic> larvae [<xref ref-type="bibr" rid="CR9">9</xref>]. Similar findings were also reported in Mexico [<xref ref-type="bibr" rid="CR10">10</xref>] and Indonesia [<xref ref-type="bibr" rid="CR11">11</xref>]. On the other hand, mother-to-infant transmission of dengue virus via cord blood or breast milk remains controversial [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec3"><title>Clinical manifestations</title><p>Based on the results from several studies, the WHO has launched a new dengue classification. This classification divides dengue cases into a) cases with/without warning signs and b) severe dengue cases [<xref ref-type="bibr" rid="CR2">2</xref>]. However, it is important to note that numerous research groups have debated the rational of this classification as it does not fit their unique local settings. The criteria for dengue case classification are presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.</p><p>Clinically, dengue infection has a broad spectrum of features. The vast majority of cases are asymptomatic and passes unnoticed. Typically, the symptoms start to be prominent after an incubation period of 3&#x02013;10 days [<xref ref-type="bibr" rid="CR15">15</xref>]. The severity of the clinical manifestations varies from mild symptoms to severe life threatening symptoms in the case of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [<xref ref-type="bibr" rid="CR16">16</xref>]. Predicting the progression of the mild signs to a severe DHF/DSS remains a challenge due to non-specificity of clinical presentation and the incomplete understanding of pathophysiology of the disease and its underlying molecular mechanisms.</p></sec><sec id="Sec4"><title>Dengue with warning signs</title><p>The early signs of the disease are non-specific. According to the WHO classification (2009), DF is characterized by febrile episode (&#x02265;40&#x000a0;&#x000b0;C for 2&#x02013;7 days) frequently associated with rash, nausea, vomiting, and headache. Although the disease affects people of all ages from infancy through to adulthood [<xref ref-type="bibr" rid="CR17">17</xref>], epidemiological data showed that children tend to tolerate this phase of illness better than adults [<xref ref-type="bibr" rid="CR18">18</xref>]. The persistence of the aforementioned symptoms and appearance of other symptoms, such as abdominal pain, mucosal bleed, and lethargy and restlessness can be seen 3&#x02013;7 days later. Laboratory analysis of mild dengue fever cases usually shows abnormal leukocyte counts and moderate elevation of the hepatic amino-transferase enzyme activity [<xref ref-type="bibr" rid="CR19">19</xref>]. The emergence of these symptoms is a warning sign for disease progression to severe form (DHF/DSS) if therapeutic intervention is not undertaken. At this stage clinical intervention and continuous surveillance are imperative to prevent vascular leakage, especially in an endemic area.</p></sec><sec id="Sec5"><title>Severe dengue</title><p>This form of dengue infection can be attributed to any of the four known serotypes DENV 1&#x02013;4. The likelihood of developing DHF/DSS is high in patients who have experienced dengue infection in the past with heterogeneous serotype [<xref ref-type="bibr" rid="CR20">20</xref>]. About 5&#x02013;10&#x000a0;% of patients progress to develop a severe DHF/DSS which can be fatal unless treated promptly [<xref ref-type="bibr" rid="CR21">21</xref>]. This form develops at a late stage of DF, where patients may go through defervescence phase characterized by a sudden drop of body&#x02019;s temperature. This phase is also distinguished by severe bleeding, particularly bleeding from the gastrointestinal tract (black, tarry stool), and thrombocytopenia (&#x0003c;50,000/mm3), which may affect up to 50&#x000a0;% of DHF cases [<xref ref-type="bibr" rid="CR22">22</xref>]. Interestingly, there was an observed negative correlation between the severity of DHF and the level of platelets in the blood. The exact mechanism of this correlation has yet to be delineated. The drop of platelet counts and the loss of their functionality lead to a vascular fragility increasing the risk of hemorrhage and plasma leakage [<xref ref-type="bibr" rid="CR23">23</xref>]. It has been suggested that during acute phase of the infection DENV replicates quickly in platelets, as this is very critical for virus survival and dissemination [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p>The existence of other symptoms such as retro-orbital pain, maculopapular rash, petechiae, or bleeding from the nose or gums will help making definitive diagnosis for DF [<xref ref-type="bibr" rid="CR25">25</xref>]. Evidence of plasma leakage in various body cavities such as the pleural cavity and the peritoneal cavity, associated with profuse perspiration, adynamia, and sometimes fainting are signs of rapid progression to shock. Subsidence in systolic pressure and hypotension may result in profound shock, known as dengue shock syndrome (DSS). The duration of DSS for a long time might predispose to further complications such as massive bleeding, disseminated intravascular coagulopathy (DIC), respiratory failure, multi-organ failure, and infrequently encephalopathy leading to death [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. It has been proposed that case fatality related to DHF may reach 15&#x000a0;% of all cases, however, proper medical care and symptomatic management can reduce mortality rate to less than 1&#x000a0;% [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec6"><title>Diagnosis</title><p>An early and accurate laboratory diagnosis of dengue infection is of paramount importance in the management of the disease. It has been estimated that the number of misdiagnosed dengue cases could reach a record ratio of 50&#x000a0;% of all cases, mainly due to a large disparity of dengue signs and symptoms which overlap with the symptoms of other viral infections, especially for persons living in or traveling to endemic areas of tropical infectious diseases. Dengue fever should be distinguished from other illnesses which share similar symptoms such as chikungunya, Mayaro fever, Ross River fever, West Nile fever, Zika fever, yellow fever and viral hemorrhagic fevers [<xref ref-type="bibr" rid="CR4">4</xref>]. Until the antiviral vaccine becomes available, the prevention of severe cases and cut-down of the economic burden of the disease rely enormously on early and accurate diagnosis. The latter is made possible through the availability of several diagnostic laboratory and virological tests.</p><p>The onset of later stage symptoms of the illness can be overwhelming and more pathognomonic. Nonetheless, based on WHO classification schemes, the appearance of leukopenia in patients with febrile illness is a major consideration in making diagnosis of dengue infection [<xref ref-type="bibr" rid="CR29">29</xref>]. Overall, there is an urgent need to reduce dengue morbidity and mortality by improving the diagnosis and molecular analysis of emerging dengue virus. Thus far, two diagnostic modalities have been applied to detect the disease at an early stage. The first one is a direct method targeting the acute phase of dengue disease, which is based upon detection of genomic RNA by RT-qPCR or soluble NS1 by antigen capture in blood samples from viremic patients. The second is the indirect method that relies on serological tests to detect dengue-related immunoglobulins par Mac-ELISA for the capture of specific IgM or indirect ELISA for the capture of anti-DEN IgGs [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>].</p></sec><sec id="Sec7"><title>Genetic alteration/susceptibility to dengue infection</title><p>Several risk factors have been associated with dengue infection and its progression to severe DHF/DSS forms. Recent advances in molecular biology have revealed that the genetic makeup of the three elements of dengue infection (the virus, the vector, and the host) plays a primordial role in the pathogenesis of the disease and could potentially contribute to the DHF progression [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Hence, an in-depth analysis of genetic variability including polymorphism and mutations could be beneficial in identifying the possible factors and mechanisms of disease development [<xref ref-type="bibr" rid="CR36">36</xref>]. The list of host&#x02019;s genetic factors that confer susceptibility or resistance to dengue infection is summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Genetic susceptibility</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene</th><th>Function</th><th>Reference</th></tr></thead><tbody><tr><td>Fc&#x003b3;RIIa</td><td>Protected from DHF</td><td>
<italic>Am. J. Trop. Med. Hyg.</italic> 2002<italic>,</italic>
<bold>67</bold>(1):</td></tr><tr><td>Vitamin D receptor (VDR)</td><td>Associated with resistance to severe dengue</td><td>Human Immunology. 2012, <bold>73</bold>: 1194&#x02013;1199.</td></tr><tr><td>IL-10</td><td>Associate with dengue disease severity</td><td>Plos one. 2012, <bold>7</bold> (11), e50387.</td></tr><tr><td>TNFa</td><td>Associate with dengue disease severity</td><td>Plos one. 2012, <bold>7</bold> (11), e50387.</td></tr><tr><td>TGFb</td><td>Associate with dengue disease severity</td><td>Plos one. 2012, <bold>7</bold> (11), e50387.</td></tr><tr><td>JAK1</td><td>Strongly association with DHF</td><td>Eur. J. Human Genet. 2010, <bold>18</bold>: 1221&#x02013;1227.</td></tr><tr><td>HLA class I alleles A*01, A*0207, A*24, B*07, B*46, B*51</td><td>DHF development</td><td>Clin Microbio Rev. 2009, <bold>22</bold> (4): 564&#x02013;581., Tissue Antigens <bold>60</bold>:309&#x02013;318.</td></tr><tr><td>HLA class II alleles DQ*1, DR*1, DR*4</td><td>DHF development</td><td>Clin Microbio Rev. 2009, <bold>22</bold> (4): 564&#x02013;581.</td></tr><tr><td>Glucose-6-phosphate dehydrogenase</td><td>Increase DENV replication</td><td>Blood Cells Mol. Dis. 2009. <bold>42</bold>:267&#x02013;278.</td></tr><tr><td>DC-SIGN</td><td>Associated with DENV infection</td><td>Med Sci (Paris). 2005, <bold>21</bold>: 905&#x02013;906.</td></tr><tr><td>TAP</td><td>Prevent DHV/DSS</td><td>Scand J Immunol <bold>67</bold>:618&#x02013;625</td></tr><tr><td>MBL</td><td>Protect against DENV</td><td>Hum Immunol <bold>69</bold>: 122&#x02013;128.</td></tr><tr><td>CTLA-4</td><td>Increases the risk of DHF.</td><td>Clin Immunol <bold>131</bold>: 404&#x02013;409.</td></tr><tr><td>MICB</td><td>Associated with severe forms of dengue</td><td>Nat Genet. <bold>43</bold>(11): 1139&#x02013;1141</td></tr><tr><td>PLCE1</td><td>Associated with severe forms of dengue</td><td>Nat Genet. <bold>43</bold>(11): 1139&#x02013;1141</td></tr><tr><td>ABO blood group</td><td>Increases the risk of DHF</td><td>J Inf Dis <bold>195</bold>:1014&#x02013;1017</td></tr><tr><td>HPA2</td><td>Enhance susceptibility to DHF</td><td>Hum Immunol <bold>68</bold>:973&#x02013;979</td></tr><tr><td>IFN-&#x003b3;</td><td>Enhance severity of dengue disease</td><td>FEMS Immunol Med Mic 2000; <bold>28</bold>: 183&#x02013;188.</td></tr><tr><td>IL-6</td><td>Associated with DSS</td><td>PLoS Negl Trop Dis. 2013, <bold>7</bold>(9): e2412.</td></tr><tr><td>VCAM-1</td><td>Associated with severe dengue</td><td>Trop Med Health. 2014, <bold>42</bold>(4): 137&#x02013;44.</td></tr><tr><td>Oligoadenylate synthetases (OAS)</td><td>Enhance susceptibility to dengue infection</td><td>Infection, Genetics and Evolution 2013, <bold>14</bold>: 390&#x02013;395.</td></tr></tbody></table><table-wrap-foot><p>List of genes that confer susceptibility to dengue infection. The journal volume is given in bold</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>The mosquito</title><p>Like most arboviruses, DENV infect different organs of the mosquito, including the salivary glands and the central nervous system. Mosquito infection elicit behavioral changes including increase of the probing time which lead to host interruption that might lead to wider spread of the virus [<xref ref-type="bibr" rid="CR37">37</xref>]. It has been demonstrated that DENV infection induced the expression of cathepsin-B, a putative cystatin, and a hypothetical ankyrin repeat-containing protein genes [<xref ref-type="bibr" rid="CR38">38</xref>]. The latter could alter the efficiency of virus replication in the salivary gland. This study has shown that modulation of <italic>OBP10</italic> and <italic>OBP22</italic> genes expression as well as DENV infection-responsive odorant-binding protein genes increase the time length for initiation of probing before a successful blood meal, resulting in changes in the host seeking behavior of the mosquito. Comparative analysis of the salivary gland transcriptomes of native and DENV-infected <italic>Ae. aegypti</italic> identified a number of differentially expressed genes related to sugar/protein digestion enzymes, immunity related genes and blood meal acquisition enzymes that might have an impact on the efficiency of viral replication or mosquito feeding behavior. This study showed that DENV infection alter the expression of key host-seeking genes in the mosquito&#x02019;s main olfactory organs and the antennae [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p>Recent updates have indicated that resistance of <italic>Ae. aegypti</italic> to conventional insecticides is related to different mechanisms, one of which is associated with genetic abnormalities within the vector&#x02019;s genome. Single point mutation in the voltage-gated sodium channel gene at position 1534 (<italic>F1534C</italic>) resulting in phenylalanine to cysteine substitution in <italic>Ae. aegypti</italic> confers resistance to permethrin. This mutation is widespread in this vector in Southeast Asia and Latin America [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. It has also been reported that a single amino acid substitution Valine to Glycine at position 1016 in domain II, segment 6 of the voltage-gated sodium channel gene was associated with less sensibility of <italic>Ae. aegypti</italic> to deltamethrin in Thailand [<xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec9"><title>Human susceptibility to dengue disease</title><p>Numerous multi-disciplinary studies confirmed that race, young age, virus strain, female sex and high body-mass index correlate well with increased burden of dengue infection. The observation that people of African background are less likely to develop DHF/DSS compared to their Caucasian counterpart has led to the suggestion that host genetic variability has a major impact on the clinical manifestations of dengue infection [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Thus, a closer consideration of human genes regulating the severity of dengue infection, especially genes associated with the immune response, might help in controlling disease spread and improve the acute symptoms of the infection. A number of studies have investigated the relationship between the host genetic polymorphisms and DENV infection (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p>A single nucleotide polymorphism (SNP) in the promoter of CD209/DC-SIGN was associated to increased risk of developing dengue fever [<xref ref-type="bibr" rid="CR44">44</xref>]. Association studies have successfully identified a link between polymorphisms in the <italic>human major-histocompatibility-complex (HLA) class I/II genes</italic> and <italic>non-HLA</italic> host genetic factors and severity of dengue disease [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref>]. Polymorphisms of the <italic>TAP1</italic> and <italic>TAP2</italic> genes could be directly associated with the risk of developing dengue disease among the primary-infected individuals [<xref ref-type="bibr" rid="CR48">48</xref>]. Both <italic>TAP1</italic> and <italic>TAP2</italic> are located within the <italic>MHC class II</italic> region and homozygosity of the <italic>TAP1</italic> at position 1333 and 1637 and for <italic>TAP2</italic> at position 2379, respectively, was found to protect against developing severe forms of dengue [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p>In an independent study [<xref ref-type="bibr" rid="CR49">49</xref>], the authors showed that single nucleotide polymorphism of the oligoadenylate synthetase genes (<italic>OAS1, 2 and 3</italic>), of the OAS/RNase L antiviral immune system, enhance susceptibility to clinical outcomes of dengue infection. An association between the severity of the disease and other genes including human leukocyte antigen class I and class II genes, tumor necrosis factor-alpha, <italic>FcGRIIA</italic>, vitamin D receptor, transporters associated with antigen presentation, and <italic>JAK1</italic> has also been proposed [<xref ref-type="bibr" rid="CR50">50</xref>]. The importance of <italic>Vit-D</italic> in DENV pathogenesis was concluded from newly-gathered data showing that <italic>Vit-D</italic> impairs DENV replication and polymorphism of <italic>Vit-D</italic> gene increases the expression of both CD209/DC-SIGN and FcGRIIA receptors that enhance DENV entry in the target cells [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>].</p><p>In another study [<xref ref-type="bibr" rid="CR53">53</xref>], the authors have successfully applied genome-wide association study (GWAS) approach to identify loci that confer susceptibility to severe forms of dengue disease. The investigators used samples from 2008 children affected with severe dengue infection against 2018 population control cases in Vietnam. The data showed that SNPs at two loci, <italic>MICB</italic> and <italic>PLCE1</italic>, significantly increased the likelihood of developing DSS in children. This finding was further validated in an independent cohort of 1737 cases and 2934 controls [<xref ref-type="bibr" rid="CR53">53</xref>]. A SNP in the <italic>MICB</italic> gene coding for the MHC class I polypeptide-related sequence B, an inducible activating ligand for the NKG2D type II receptor of immune cells could alter the protective role of natural killer and CD8<sup>+</sup> T cells in the host responsiveness to DENV at the early stage of infection [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. On the other hand, <italic>PLCE1</italic> plays a primordial role in maintaining intact vascular endothelial cell barrier function, hence, polymorphism of the <italic>PLCE1</italic> gene may lead to blood vessels leakage and circulatory hypovolemia during DSS [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p>Other host candidate genes have also been associated with early onset dengue disease. Among these genes, there were receptors/attachment factors for DENV linked to immune system and inflammatory response. The chemokines CXCL10, CXCL11 and its respective chemokine receptor CXCR3 were reported as biomarkers for severe form of dengue infection [<xref ref-type="bibr" rid="CR57">57</xref>]. These results are in agreement with recent emerging data indicating strong association between CXCL10, CXCL11 and CXCR3 and vascular permeability [<xref ref-type="bibr" rid="CR58">58</xref>]. The three genes are components of the NF-kB pathway and are involved in the pathogenesis of SARS and West Nile virus encephalitis [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Cerney et al<italic>.</italic> (2014) interrogated the effect of DENV on the first point of human contact which is skin cells. The authors demonstrated an increase expression of IFN-&#x003b2;, STAT-1 and CCL5 in a susceptible population of skin dendritic cells (DC) which may facilitate the spread of DENV in the blood [<xref ref-type="bibr" rid="CR61">61</xref>]. This process depends enormously on vector-derived salivary factors inoculated on the skin cells [<xref ref-type="bibr" rid="CR62">62</xref>].</p></sec><sec id="Sec10"><title>Current status of dengue vaccine development</title><p>Till-date, there is no effective, commercially available, therapy/vaccine for dengue virus. Numerous groups have already made intensive efforts and made good progress to develop a safe, affordable and effective vaccine against all serotypes for global public health [<xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR69">69</xref>]. Vaccines which are being developed use various approaches such as live attenuated viruses, inactivated viruses, subunit vaccines, DNA vaccines, and chimeric viruses using yellow fever vaccine and attenuated dengue viruses as backbones (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Current status of dengue vaccine development</p></caption><table frame="hsides" rules="groups"><thead><tr><th>No</th><th>Strategy</th><th>Developer (s)</th><th>Current status</th></tr></thead><tbody><tr><td>1</td><td>Live attenuated yellow fever 17D/DENV chimeric vaccine</td><td>Sanofi-Pasteur</td><td>Phase 3 trials with a tetravalent formulation in DENV endemic countries</td></tr><tr><td>2</td><td>PDK cell-passaged, live attenuated vaccine</td><td>WRAIR/GSK</td><td>Phase 2 trials with a tetravalent formulation in endemic countries</td></tr><tr><td rowspan="2">3</td><td rowspan="2">Live attenuated DENV Delta-30 mutation and intertypic DENV chimeric vaccines</td><td rowspan="2">NIH/Johns Hopkins</td><td>Phase 1/2 trials with monovalent formulations completed; tetravalent</td></tr><tr><td>phase 1 initiated</td></tr><tr><td>4</td><td>Dengue prM-E DNA vaccine</td><td>NMRC</td><td>Phase 1 with monovalent vaccine completed</td></tr><tr><td>5</td><td>Recombinant 80&#x000a0;% E subunit antigen vaccine</td><td>Hawaii Biotech/Merck</td><td>Phase 1 with monovalent vaccine initiated</td></tr><tr><td>6</td><td>Purified inactivated vaccine</td><td>WRAIR</td><td>Phase 1 with monovalent vaccine initiated</td></tr><tr><td>7</td><td>Live attenuated chimeric DENV vaccine</td><td>CDC</td><td>Phase 1 with monovalent vaccine initiated</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: PDK, primary dog kidney cells; WRAIR, Walter Reed Army Institute of Research; GSK, GlaxoSmithKline Biologicals; NIH, National Institutes of Health; prM-E, premembrane-envelope; NMRC, Naval Medical Research Center; CDC, Centers of Disease Control and Prevention</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Live attenuated yellow fever 17D/DENV chimeric vaccine</title><p>Currently, only one tetravalent vaccine against dengue virus, developed by Sanofi-Pasteur (France) has reached phase III clinical trial and is expected to be launched in 2015. This vaccine is based on the production of four chimeric live dengue-yellow fever viruses in which the yellow fever (YF) 17D vaccine sequences encoding the envelope proteins prM and E genes were substituted by the prM and E genes from DV of serotype 1, 2, 3, or 4 in a molecular clone of YF-17D [<xref ref-type="bibr" rid="CR69">69</xref>]. This vaccine was produced and tested over 6000 people using four dengue virus isolates from Indonesia and Thailand. This candidate vaccine was found to be attenuated and stable in animal models with respect to plaque size and yellow fever virus neurotropism [<xref ref-type="bibr" rid="CR70">70</xref>]. Results of the clinical trials showed no adverse effects except moderate injection site pain, headache, and myalgia. Another randomized, controlled trial was launched using a total of 4002 Thai school children to investigate the efficacy of a recombinant, tetravalent vaccine for dengue virus and only 134 dengue cases were reported [<xref ref-type="bibr" rid="CR71">71</xref>]. Phase I trial of the vaccine in the Philippines showed that the seropositivity increased gradually (53, 72 &#x00026; 92&#x000a0;%) after 1&#x02013;3 vaccinations against all four serotypes as compared to control group. The most promising results were observed in children 2&#x02013;5 years old who exhibited high levels of reactivity of 91, 100, 96, 100&#x000a0;% for DENV 1&#x02013;4; respectively [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p>Another placebo-controlled trial was conducted on 10,275 children from Vietnam (vaccine, <italic>n</italic>&#x02009;=&#x02009;6851 Vs placebo, <italic>n</italic>&#x02009;=&#x02009;3424) to determine the clinical efficacy and safety of CYD-TDV. The results demonstrated virologically-confirmed cases in 47&#x000a0;% of the vaccine group as compared to the control group (53&#x000a0;%). The efficacy was achieved in up to 56.5&#x000a0;% (95&#x000a0;% CI 43.8&#x02013;66.4). These findings indicated that the vaccine is highly efficacious with good safety profile when three injections were given to children with age group 2&#x02013;14 years at 0, 6 and 12&#x000a0;months intervals [<xref ref-type="bibr" rid="CR73">73</xref>]. The data emerging from another randomized phase II trial in India indicated that the vaccine has no serious adverse events and the immunogenicity and safety of CYD-TDV were satisfactory [<xref ref-type="bibr" rid="CR74">74</xref>]. A pilot study carried out in five Latin American countries where more than 20,000 children aged 9&#x02013;16 were recruited to receive either the CYD-TDV vaccine or placebo. The results on efficacy (60.8&#x000a0;%) and safety profiles were consistent with the previous findings [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. Interestingly, the vaccine efficacy (80.3&#x000a0;%) against hospitalization for dengue was promising and represented a step forward to developing an effective dengue vaccine [<xref ref-type="bibr" rid="CR75">75</xref>].</p></sec><sec id="Sec12"><title>Live attenuated DENV delta-30 mutation and intertypic DENV chimeric vaccines</title><p>Other candidate dengue vaccines have been developed in USA by the Johns Hopkins University and National Institute of Allergy and Infectious Diseases (NIAID) and have reached advanced clinical trials [<xref ref-type="bibr" rid="CR65">65</xref>]. Four live-attenuated DENV/delta-30 were generated each containing 30 nucleotides deletion of the 3&#x02019;-untranslated region of genomic RNA (delta-30). These vaccines efficiently impaired viral growth in human liver carcinoma cells [<xref ref-type="bibr" rid="CR76">76</xref>]. To improve the attenuation of DENV-2/delta-30 and DENV-3/delta-30, chimeric DENV were developed by substitution of the <italic>prM-E</italic> gene region of DENV-4/delta-30 virus with the prM-E genes of DENV-2 and DENV-3 [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. The results from phase I clinical trial showed that all four live-attenuated DENV/delta-30 are safe and immunogenic with minor side effects such as faint rash and transient leucopenia only after higher dose [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>].</p></sec><sec id="Sec13"><title>Dengue-measles vaccine</title><p>Dengue virus serotype-1 antigen was expressed in a vector based on pediatric live-attenuated Schwarz measles vaccine (MV) by using the envelope domain III (EDIII) fused with the ectodomain of the membrane protein (ectoM). After immunization, long-term production of DENV-1 serotype-specific neutralizing antibodies was observed in measles virus susceptible mice [<xref ref-type="bibr" rid="CR80">80</xref>]. A new strategy was evaluated based on single minimal tetravalent DENV antigen expression using viral vector derived from pediatric live-attenuated measles vaccine (MV). A recombinant MV vaccine construct was developed using envelope domain III (EDIII) and ectodomain of the membrane protein. The neutralizing antibodies were induced against all four serotypes of dengue virus after two injections in mice susceptible to MV infection. A strong memory neutralizing response was observed against all four serotypes in immunized mice after inoculation with live DENV from each serotype [<xref ref-type="bibr" rid="CR81">81</xref>].</p></sec><sec id="Sec14"><title>Dengue prM-E DNA vaccine</title><p>A naked DNA-based candidate vaccine against DENV has been developed by the Naval Medical Research Center [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. The genes encoding prM and E of DENV were cloned into a shuttle vector under the transcriptional control of human cytomegalovirus (CMV) promoter. The results of phase I clinical trial showed no adverse effects except mild injection site pain, swelling, and fatigue. After second dose, strong IgM and IgG antibody response was observed which favors the safety profile of this vaccine. To get a better immunogenicity profile, a vaccine based on lipid adjuvant Vaxfectin (Vical Incorporated, San Diego, USA), was developed and the results demonstrated good protection profile against DENV compared to DNA alone [<xref ref-type="bibr" rid="CR84">84</xref>]. Based on this technology, different groups have developed other candidate vaccines and achieved good protection in mouse models using envelope glycoproteins prM and E, the non-structural protein NS1 and the helicase/protease NS3 as vaccine antigens [<xref ref-type="bibr" rid="CR85">85</xref>&#x02013;<xref ref-type="bibr" rid="CR87">87</xref>].</p></sec><sec id="Sec15"><title>Purified inactivated vaccine (PIV)</title><p>The first purified inactivated vaccine was developed with aluminum hydroxide (alum) adjuvant and tested in mice and rhesus macaques in the mid-1990s, by Walter Reed Army Institute of Research against dengue 2 serotype and good virus protection was reported after two doses [<xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR89">89</xref>]. Using similar technology, second generation Japanese encephalitis (JE) PIV vaccine was developed [<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. Currently, a new JE vaccine (Ixiaro; Novartis Vaccines) has been approved for use in many countries, including the USA [<xref ref-type="bibr" rid="CR92">92</xref>]. Another dengue vaccine (dengue 1 PIV), recombinant subunit dengue E glycoprotein antigen (r80E) was also developed and has entered phase I clinical trial [<xref ref-type="bibr" rid="CR93">93</xref>&#x02013;<xref ref-type="bibr" rid="CR95">95</xref>]. The Centers for Disease Control and Prevention (USA) have also developed a live-attenuated vaccine named DENVax, which was found to be highly immunogenic in both children and adults and has currently entered phase I clinical trial in the United States [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. Recently, a novel third generation approach is being used to develop a vaccine containing recombinant subunit E domain III (<italic>ED3</italic>) and the results of laboratory tests have shown the development of potent neutralizing antibodies in a mouse model [<xref ref-type="bibr" rid="CR98">98</xref>&#x02013;<xref ref-type="bibr" rid="CR100">100</xref>]. Using the same technology, a tetravalent vaccine was developed and expressed in <italic>Pichia pastoris</italic> by splicing and using flexible pentaglycyl linkers of the four EDIII. The observed results showed that this antigen elicit specific antibodies against all four DENV serotypes in BALB/c mice [<xref ref-type="bibr" rid="CR101">101</xref>].</p></sec><sec id="Sec16"><title>Lessons from animal models</title><p>Animal models are very useful for vaccine test development. The lack of animal models significantly hampered the development and efficacy testing of dengue vaccine. Currently only rhesus macaques and <italic>Aotus</italic> monkeys are being used for testing the vaccine before clinical trials are initiated [<xref ref-type="bibr" rid="CR62">62</xref>]. The D1ME100 vaccine was evaluated in both <italic>Aotus</italic> monkeys and rhesus monkeys, and found to be immunogenic with 80&#x02013;95&#x000a0;% protection against dengue infection [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]. Porter et al. (2012) demonstrated that injection of non-human primate with three doses on day 1, 28 and 84, with tetravalent dengue DNA vaccine Vaxfectin-adjuvanted, was more efficient against live dengue-2 virus compared to control animals. This finding support initiation of Vaxfectin-adjuvanted phase I clinical trial [<xref ref-type="bibr" rid="CR84">84</xref>].</p><p>Successful induction of immune response was obtained in mice and rhesus monkeys to the vaccines developed using dengue 4 prM-E, dengue 1 <italic>prM-E-nonstructural (NS)1</italic>, and dengue 2 NS3 antigens, and PIV adjuvanted with alum [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. Centers for Disease Control and Prevention (Fort Collins, CO), Hawaii biotech, and Simmons developed different vaccines that showed good immunogenicity in animal models [<xref ref-type="bibr" rid="CR104">104</xref>]. Similarly, the psoralen/UV inactivation dengue vaccine was found to be more immunogenic and protective against dengue serotype 1 virus in <italic>Aotus</italic> monkeys [<xref ref-type="bibr" rid="CR105">105</xref>].</p></sec><sec id="Sec17"><title>Antiviral therapy</title><p>Thus far, there are no antiviral drugs available to treat dengue fever; therefore the community will continue to depend on the control of the mosquito vector as the main route to prevent the spread of disease. Alternative approaches have been utilized against flaviviruses by targeting and inhibiting virus entry and the essential elements used in virus replication, nonstructural proteins, RNA polymerase, and proteases. The most important target elements include NS3 helicase nucleoside triphosphatase (NTPase/RNA 5&#x02019; triphosphatase (RTPase), NS5 methyl transferase/RNA-dependent RNA polymerase, and NS3/NS2B protease [<xref ref-type="bibr" rid="CR106">106</xref>&#x02013;<xref ref-type="bibr" rid="CR108">108</xref>].</p><p>RNA interference (RNAi) technology is also being used to impair virus replication against respiratory syncytial virus, hepatitis viruses, influenza virus, poliovirus and HIV [<xref ref-type="bibr" rid="CR109">109</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. Low molecular weight phenolic compounds such as flavonoids and phytochemicals isolated from plants were previously tested and are being used for anti-dengue therapy [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. An anti-viral inhibitory effect ranging from 50&#x02013;75&#x000a0;% against DENV replication was observed when methanolic extracts of <italic>Momordica charantia</italic> and <italic>Andrographis paniculata</italic> were used in cultured primate cells [<xref ref-type="bibr" rid="CR113">113</xref>].</p><p>Several attempts have been made in the past to tackle dengue through elimination of <italic>Ae. Aegypti.</italic> The most successful experiences were related to vector control programs adopted in Cuba and Singapore. The programs were based on intensive insecticidal treatment and reduction of the availability of Aedes larval habitats [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR114">114</xref>]. Unfortunately, lack of sustainability of these stringent measures led to reappearance of dengue outbreaks.</p><p>Recently, a novel form of biological control of dengue transmission has been developed and is currently being applied. This is based on the development of genetically modified (GM) mosquitoes infected with a bacterium known as Wolbachia to combat dengue infection. This bacterium blocks replication of the virus inside the mosquito and prevents its transmission to humans [<xref ref-type="bibr" rid="CR115">115</xref>]. In 2012, 10 million GM male mosquitoes were released in the wild to decrease the number of <italic>Aedes</italic> mosquitoes and reduce the rate of dengue transmission. A closer monitoring of the insects revealed that over 85&#x000a0;% of the eggs were Wolbachia-positive which indicated that GM-mosquitoes were overriding wild-mosquitoes resulting in decreased virus transmission [<xref ref-type="bibr" rid="CR116">116</xref>]. In an initiative to eradicate dengue fever, scientists from Australia, are leading Eliminate Dengue (ED) program which involves community engagement as a key component in this program. Since the program kicked off in 2011, millions of Wolbachia mosquitoes were released across the North Queensland city&#x02014;Australia. Based on the promising results obtained from local trial, Eliminate Dengue became an international research program across countries affected by dengue including Australia, Vietnam, Indonesia, Brazil and Colombia [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>].</p></sec><sec id="Sec18"><title>Targets of antiviral therapy</title><p>Dengue infection can be prevented by alternative approaches. The first one includes blocking virus entry into cells which is mediated by the viral envelope glycoprotein E via receptor-mediated endocytosis [<xref ref-type="bibr" rid="CR119">119</xref>]. Dendritic cells, monocytes, and macrophages are the main targets of DENV infectious entry. The second approach involves blocking virus attachment to specific cellular receptors expressed on immune cells, liver cells, and endothelial cells.</p></sec><sec id="Sec19"><title>Fusion and glycosidase inhibitors</title><p>Small molecules and peptides targeting the hydrophobic pocket of the envelope E glycoprotein are characterized as inhibitors of virus entry. Nicholson et al. (2011) explored the inhibitory effects of DN59 and 1OAN1, peptide entry inhibitors. The authors demonstrated that DN59 and 1OAN1 can effectively block antibody dependent enhancement (ADE) <italic>in-vitro</italic> suggesting that entry inhibitors are potential candidates to prevent development of DHF/DSS [<xref ref-type="bibr" rid="CR120">120</xref>]. Two other compounds have also been shown to qualify as potent inhibitors of dengue virus infection are imino-sugars deoxynojirimycin and castanospermine [<xref ref-type="bibr" rid="CR121">121</xref>]. These compounds are natural alkaloids derived from the black bean and act as inhibitors against all 4 dengue serotypes by disrupting the folding pathways of the envelope glycoproteins prM and E [<xref ref-type="bibr" rid="CR122">122</xref>].</p></sec><sec id="Sec20"><title>Carbohydrate-binding agents</title><p>Various types of carbohydrate-binding agents, isolated from different organisms, have been shown to have anti-viral activities. Three plant lectins, <italic>Hippeastrum hybrid</italic> agglutinin, <italic>Galanthus nivalis</italic> agglutinin and <italic>Urtica dioica</italic> agglutinin isolated from amaryllis, snowdrop and stinging nettle respectively were found to be potent inhibitors of DENV-2 infection by inhibiting viral replication [<xref ref-type="bibr" rid="CR123">123</xref>].</p></sec><sec id="Sec21"><title>Heparan mimetics</title><p>Heparan sulfate (HS) is a putative receptor for DENV which interacts with domain III of the E-protein. Virus entry can be blocked by targeting the E-protein-HS interaction with soluble GAGs and other highly charged HS [<xref ref-type="bibr" rid="CR124">124</xref>]. Fucoidan was isolated from marine algae and showed antiviral activity against DENV-2 in BHK cells [<xref ref-type="bibr" rid="CR125">125</xref>]. Similarly, carrageenan and DL galactan, sulfated polysaccharides from red seaweeds, exhibited strong antiviral activity against DENV-2 and DENV-3 but a very weak activity against DENV-4 and DENV-1. Furthermore, two <italic>&#x003b1;</italic>-D-glucans were isolated from a Chinese herb and demonstrated high anti-DENV-2 activities in BHK cells [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR126">126</xref>].</p></sec></sec><sec id="Sec22"><title>Conclusions</title><p>Dengue fever represents a real economic burden especially in affected countries. Extensive efforts are needed to tackle disease spread and reduce the mortality rates and the associated healthcare cost. There is a need for more scientific research which we believe is a key route to provide further insight in the pathogenesis of dengue infection and help understanding the underlying molecular mechanisms associated with progression to the severe forms of the disease (DHF/DSS). This will be a step forward to develop an adequate preventive vaccine and effective treatment.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>DENV</term><def><p>Dengue virus</p></def></def-item><def-item><term>DF</term><def><p>Dengue fever</p></def></def-item><def-item><term>DHF</term><def><p>Dengue hemorrhagic fever</p></def></def-item><def-item><term>DSS</term><def><p>Dengue shock syndrome</p></def></def-item><def-item><term>DC</term><def><p>Dendritic cells</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors disclose that there is no conflict of interest.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>TN Participated in the review design, coordination and helped to draft the manuscript. SK and SS Participated in the review design and helped to draft the manuscript. PD Participated in the article revision. GD and EA Participated in the review design. Read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This Project is funded by the King Abdulaziz City for Science and Technology (KACST) under grant number <bold>(&#x00627;&#x0062a;-33-26)</bold>. The authors are also grateful to the kind cooperation provided by the Deanship of Scientific Research (DSR), King Abdulaziz University.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>KF</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name></person-group><article-title>Diagnosis of dengue: An update</article-title><source>Expert Rev Anti Infect Ther</source><year>2012</year><volume>10</volume><issue>8</issue><fpage>895</fpage><lpage>907</lpage><?supplied-pmid 23030329?><pub-id pub-id-type="pmid">23030329</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">WHO: Dengue. Guidelines for diagnosis, treatment prevention and control, Geneva, World Health Organization, 2009, WHO/HTM/NTD/DEN/2009. (<ext-link ext-link-type="uri" xlink:href="http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf">http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf</ext-link>)</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>S</given-names></name><name><surname>Gething</surname><given-names>PW</given-names></name><name><surname>Brady</surname><given-names>OJ</given-names></name><name><surname>Messina</surname><given-names>JP</given-names></name><name><surname>Farlow</surname><given-names>AW</given-names></name><name><surname>Moyes</surname><given-names>CL</given-names></name><etal/></person-group><article-title>The global distribution and burden of dengue</article-title><source>Nature</source><year>2013</year><volume>496</volume><issue>7446</issue><fpage>504</fpage><lpage>7</lpage><?supplied-pmid 23563266?><pub-id pub-id-type="pmid">23563266</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malavige</surname><given-names>GN</given-names></name><name><surname>Fernando</surname><given-names>S</given-names></name><name><surname>Fernando</surname><given-names>DJ</given-names></name><name><surname>Seneviratne</surname><given-names>SL</given-names></name></person-group><article-title>Dengue viral infections</article-title><source>Postgrad Med J</source><year>2004</year><volume>80</volume><fpage>588</fpage><lpage>601</lpage><?supplied-pmid 15466994?><pub-id pub-id-type="pmid">15466994</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madani</surname><given-names>TA</given-names></name><name><surname>Abuelzein</surname><given-names>EL-TM</given-names></name><name><surname>Al-Bar</surname><given-names>HM</given-names></name><name><surname>Azhar</surname><given-names>EI</given-names></name><name><surname>Kao</surname><given-names>M</given-names></name><name><surname>Alshoeb</surname><given-names>HO</given-names></name><etal/></person-group><article-title>Outbreak of viral hemorrhagic fever caused by dengue virus type 3 in Al-Mukalla, Yemen</article-title><source>BMC Infect Dis</source><year>2013</year><volume>14</volume><issue>13</issue><fpage>136</fpage><pub-id pub-id-type="pmid">23497142</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azhar</surname><given-names>EI</given-names></name><name><surname>Hashem</surname><given-names>AM</given-names></name><name><surname>El-Kafrawy</surname><given-names>SA</given-names></name><name><surname>Abol-Ela</surname><given-names>S</given-names></name><name><surname>Abd-Alla</surname><given-names>AM</given-names></name><name><surname>Sohrab</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Complete genome sequencing and phylogenetic analysis of dengue type 1 virus isolated from Jeddah, Saudi Arabia</article-title><source>Virol J</source><year>2015</year><volume>12</volume><fpage>1</fpage><?supplied-pmid 25591713?><pub-id pub-id-type="pmid">25591713</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Normile</surname><given-names>D</given-names></name></person-group><article-title>Surprising new dengue virus throws a spanner in disease control efforts</article-title><source>Science</source><year>2013</year><volume>342</volume><issue>6157</issue><fpage>415</fpage><?supplied-pmid 24159024?><pub-id pub-id-type="pmid">24159024</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angel</surname><given-names>B</given-names></name><name><surname>Joshi</surname><given-names>V</given-names></name></person-group><article-title>Distribution and seasonality of vertically transmitted dengue viruses in Aedes mosquitoes in arid and semi-arid areas of Rajasthan</article-title><source>India J Vector Borne Dis</source><year>2008</year><volume>45</volume><fpage>56</fpage><lpage>59</lpage><?supplied-pmid 18399318?><pub-id pub-id-type="pmid">18399318</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>V</given-names></name><name><surname>Alencar</surname><given-names>C</given-names></name><name><surname>Kamimura</surname><given-names>M</given-names></name><name><surname>de Carvalho Arau&#x02019;jo</surname><given-names>F</given-names></name><name><surname>De Simone</surname><given-names>S</given-names></name><name><surname>Dutra</surname><given-names>R</given-names></name><etal/></person-group><article-title>Occurrence of natural vertical transmission of dengue-2 and dengue-3 viruses in Aedes aegypti and Aedes albopictus in Fortaleza, Ceara&#x02019;, Brazil</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>7</issue><fpage>e41386</fpage><?supplied-pmid 22848479?><pub-id pub-id-type="pmid">22848479</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000fc;nther</surname><given-names>J</given-names></name><name><surname>Martinez-Munoz</surname><given-names>JP</given-names></name><name><surname>P&#x000e9;rez-Ishiwara</surname><given-names>DG</given-names></name><name><surname>Salas-Benito</surname><given-names>J</given-names></name></person-group><article-title>Evidence of vertical transmission of dengue virus in two endemic localities in the State of Oaxaca, Mexico</article-title><source>Intervirology</source><year>2007</year><volume>50</volume><fpage>347</fpage><lpage>352</lpage><?supplied-pmid 17700030?><pub-id pub-id-type="pmid">17700030</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulyatno</surname><given-names>KC</given-names></name><name><surname>Yamanaka</surname><given-names>A</given-names></name><name><surname>Yotopranoto</surname><given-names>S</given-names></name><name><surname>Konishi</surname><given-names>E</given-names></name></person-group><article-title>Vertical transmission of dengue virus in Aedes aegypti collected in Surabaya, Indonesia, during 2008&#x02013;2011</article-title><source>Jpn J Infect Dis</source><year>2012</year><volume>65</volume><fpage>274</fpage><lpage>276</lpage><?supplied-pmid 22627316?><pub-id pub-id-type="pmid">22627316</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phongsamart</surname><given-names>W</given-names></name><name><surname>Yoksan</surname><given-names>S</given-names></name><name><surname>Vanaprapa</surname><given-names>N</given-names></name><name><surname>Chokephaibulkit</surname><given-names>K</given-names></name></person-group><article-title>Dengue virus infection in late pregnancy and transmission to the infants</article-title><source>Pediatr Infect Dis J</source><year>2008</year><volume>27</volume><issue>6</issue><fpage>500</fpage><lpage>4</lpage><?supplied-pmid 18434933?><pub-id pub-id-type="pmid">18434933</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kariyawasam</surname><given-names>S</given-names></name><name><surname>Senanayake</surname><given-names>H</given-names></name></person-group><article-title>Dengue infections during pregnancy: Case series from a tertiary care hospital in Sri Lanka</article-title><source>J Infect Dev Ctries</source><year>2010</year><volume>4</volume><issue>11</issue><fpage>767</fpage><lpage>775</lpage><?supplied-pmid 21252457?><pub-id pub-id-type="pmid">21252457</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barthel</surname><given-names>A</given-names></name><name><surname>Gourinat</surname><given-names>A-C</given-names></name><name><surname>Cazorla</surname><given-names>C</given-names></name><name><surname>Joubert</surname><given-names>C</given-names></name><name><surname>Dupont-Rouzeyrol</surname><given-names>M</given-names></name><name><surname>Descloux</surname><given-names>E</given-names></name></person-group><article-title>Breast milk as a possible route of vertical transmission of dengue virus?</article-title><source>Clin Infect Dis</source><year>2013</year><volume>57</volume><issue>3</issue><fpage>415</fpage><lpage>7</lpage><?supplied-pmid 23575200?><pub-id pub-id-type="pmid">23575200</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>M</given-names></name><name><surname>Johansson</surname><given-names>AM</given-names></name></person-group><article-title>The incubation periods of dengue viruses</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>11</issue><fpage>e50972</fpage><?supplied-pmid 23226436?><pub-id pub-id-type="pmid">23226436</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guha-Sapir</surname><given-names>D</given-names></name><name><surname>Schimmer</surname><given-names>B</given-names></name></person-group><article-title>Dengue fever new paradigms for a changing epidemiology</article-title><source>Emerg Themes Epidemiol</source><year>2005</year><volume>2</volume><fpage>1</fpage><lpage>10</lpage><?supplied-pmid 15743532?><pub-id pub-id-type="pmid">15743532</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>NA</given-names></name><name><surname>Azhar</surname><given-names>EI</given-names></name><name><surname>El-Fiky</surname><given-names>S</given-names></name><name><surname>Madani</surname><given-names>HH</given-names></name><name><surname>Abuljadial</surname><given-names>MA</given-names></name><name><surname>Ashshi</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Clinical profile and outcome of hospitalized patients during first outbreak of dengue in Makkah, Saudi Arabia</article-title><source>Acta Trop</source><year>2008</year><volume>105</volume><issue>1</issue><fpage>39</fpage><lpage>44</lpage><?supplied-pmid 17983609?><pub-id pub-id-type="pmid">17983609</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>EE</given-names></name><name><surname>Goh</surname><given-names>KT</given-names></name><name><surname>Gubler</surname><given-names>JD</given-names></name></person-group><article-title>Dengue prevention and 35 years of vector control in Singapore</article-title><source>Emerg Infect Dis</source><year>2006</year><volume>12</volume><issue>6</issue><fpage>887</fpage><lpage>893</lpage><?supplied-pmid 16707042?><pub-id pub-id-type="pmid">16707042</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>CP</given-names></name><name><surname>Farrar</surname><given-names>JJ</given-names></name><name><surname>Vinh</surname><given-names>CN</given-names></name><name><surname>Wills</surname><given-names>B</given-names></name></person-group><article-title>Dengue</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>1423</fpage><lpage>1432</lpage><?supplied-pmid 22494122?><pub-id pub-id-type="pmid">22494122</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>JG</given-names></name><name><surname>Ooi</surname><given-names>EE</given-names></name><name><surname>Tolfvenstam</surname><given-names>T</given-names></name><name><surname>Leo</surname><given-names>YS</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Ng</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Early dengue infection and outcome study (EDEN) - study design and preliminary findings</article-title><source>Ann Acad Med Singapore</source><year>2006</year><volume>35</volume><issue>11</issue><fpage>783</fpage><lpage>9</lpage><?supplied-pmid 17160194?><pub-id pub-id-type="pmid">17160194</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wichmann</surname><given-names>O</given-names></name><name><surname>Jelinek</surname><given-names>T</given-names></name></person-group><article-title>Dengue in travelers. A Review</article-title><source>J Travel Med</source><year>2004</year><volume>11</volume><fpage>161</fpage><lpage>170</lpage><?supplied-pmid 15710058?><pub-id pub-id-type="pmid">15710058</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peeling</surname><given-names>RW</given-names></name><name><surname>Artsob</surname><given-names>H</given-names></name><name><surname>Pelegrino</surname><given-names>JL</given-names></name><name><surname>Buchy</surname><given-names>P</given-names></name><name><surname>Cardosa</surname><given-names>MJ</given-names></name><name><surname>Devi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evaluation of diagnostic tests: Dengue</article-title><source>Nat Rev Microbiol</source><year>2010</year><volume>8</volume><issue>12 Suppl</issue><fpage>S30</fpage><lpage>8</lpage><?supplied-pmid 21548185?><pub-id pub-id-type="pmid">21548185</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schexneider</surname><given-names>KI</given-names></name><name><surname>Reedy</surname><given-names>EA</given-names></name></person-group><article-title>Thrombocytopenia in dengue fever</article-title><source>Curr Hematol Rep</source><year>2005</year><volume>4</volume><issue>2</issue><fpage>145</fpage><lpage>8</lpage><?supplied-pmid 15720964?><pub-id pub-id-type="pmid">15720964</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martina</surname><given-names>BE</given-names></name><name><surname>Koraka</surname><given-names>P</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name></person-group><article-title>Dengue virus pathogenesis</article-title><source>Integr View Clin Microbiol Rev</source><year>2009</year><volume>22</volume><issue>4</issue><fpage>564</fpage><lpage>581</lpage></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noisakran</surname><given-names>S</given-names></name><name><surname>Kulkanya</surname><given-names>C</given-names></name><name><surname>Pucharee</surname><given-names>S</given-names></name><name><surname>Nattawat</surname><given-names>O</given-names></name><name><surname>Hui-Mien</surname><given-names>H</given-names></name><name><surname>Francois</surname><given-names>V</given-names></name><etal/></person-group><article-title>A re-evaluation of the mechanisms leading to dengue hemorrhagic fever</article-title><source>Ann NY Acad Sci</source><year>2009</year><volume>1171</volume><fpage>E24</fpage><lpage>E35</lpage><?supplied-pmid 19751399?><pub-id pub-id-type="pmid">19751399</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>N</given-names></name><name><surname>Gan</surname><given-names>VC</given-names></name><name><surname>Leo</surname><given-names>YS</given-names></name></person-group><article-title>Dengue myocarditis in Singapore: Two case reports</article-title><source>Infection</source><year>2013</year><volume>41</volume><issue>3</issue><fpage>709</fpage><lpage>14</lpage><?supplied-pmid 23277366?><pub-id pub-id-type="pmid">23277366</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>UK</given-names></name><name><surname>Kalita</surname><given-names>J</given-names></name><name><surname>Syam</surname><given-names>UK</given-names></name><name><surname>Dhole</surname><given-names>TN</given-names></name></person-group><article-title>Neurological manifestations of dengue virus infection</article-title><source>J Neurol Sci</source><year>2006</year><volume>244</volume><issue>1&#x02013;2</issue><fpage>117</fpage><lpage>22</lpage><?supplied-pmid 16524594?><pub-id pub-id-type="pmid">16524594</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubler</surname><given-names>DJ</given-names></name></person-group><article-title>Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century</article-title><source>Trends Microbiol</source><year>2002</year><volume>10</volume><issue>2</issue><fpage>3</fpage><lpage>100</lpage></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>GJ</given-names></name><name><surname>Ong</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>LK</given-names></name><name><surname>Shera</surname><given-names>C</given-names></name><name><surname>Angelia</surname><given-names>C</given-names></name><name><surname>Wen</surname><given-names>YL</given-names></name><etal/></person-group><article-title>The early clinical features of dengue in adults: Challenges for early clinical diagnosis</article-title><source>PLoS Negl Trop Dis</source><year>2011</year><volume>5</volume><issue>5</issue><fpage>e1191</fpage><?supplied-pmid 21655307?><pub-id pub-id-type="pmid">21655307</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcon-LePoder</surname><given-names>S</given-names></name><name><surname>Sivard</surname><given-names>P</given-names></name><name><surname>Drouet</surname><given-names>MT</given-names></name><name><surname>Talarmin</surname><given-names>A</given-names></name><name><surname>Rice</surname><given-names>C</given-names></name><name><surname>Flamand</surname><given-names>M</given-names></name></person-group><article-title>Secretion of flaviviral non-structural protein NS1: From diagnosis to pathogenesis</article-title><source>Novartis Found Symp</source><year>2006</year><volume>277</volume><fpage>233</fpage><lpage>47</lpage><?supplied-pmid 17319166?><pub-id pub-id-type="pmid">17319166</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanluca</surname><given-names>C</given-names></name><name><surname>Mazzarotto</surname><given-names>GA</given-names></name><name><surname>Bordignon</surname><given-names>J</given-names></name><name><surname>Duarte Dos Santos</surname><given-names>CN</given-names></name></person-group><article-title>Development, characterization and application of monoclonal antibodies against Brazilian dengue virus isolates</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>11</issue><fpage>e110620</fpage><?supplied-pmid 25412181?><pub-id pub-id-type="pmid">25412181</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dos Santos</surname><given-names>HW</given-names></name><name><surname>Poloni</surname><given-names>TR</given-names></name><name><surname>Souza</surname><given-names>KP</given-names></name><name><surname>Muller</surname><given-names>VD</given-names></name><name><surname>Tremeschin</surname><given-names>F</given-names></name><name><surname>Nali</surname><given-names>LC</given-names></name><etal/></person-group><article-title>A simple one-step real-time RT-PCR for diagnosis of dengue virus infection</article-title><source>J Med Virol</source><year>2008</year><volume>80</volume><issue>8</issue><fpage>1426</fpage><lpage>33</lpage><?supplied-pmid 18551599?><pub-id pub-id-type="pmid">18551599</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>PY</given-names></name><name><surname>Huang</surname><given-names>JH</given-names></name></person-group><article-title>Current advances in dengue diagnosis</article-title><source>Clin Vaccine Immunol</source><year>2004</year><volume>11</volume><issue>4</issue><fpage>642</fpage><lpage>650</lpage></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordeiro</surname><given-names>MT</given-names></name><name><surname>Braga-Neto</surname><given-names>U</given-names></name><name><surname>Nogueira</surname><given-names>RR</given-names></name><name><surname>Marques</surname><given-names>TE</given-names></name></person-group><article-title>Reliable classifier to differentiate primary and secondary acute dengue infection based on IgG ELISA</article-title><source>PloS One</source><year>2009</year><volume>4</volume><issue>4</issue><fpage>e4945</fpage><?supplied-pmid 19340301?><pub-id pub-id-type="pmid">19340301</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vannberg</surname><given-names>FO</given-names></name><name><surname>Chapman</surname><given-names>SJ</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name></person-group><article-title>Human genetic susceptibility to intracellular pathogens</article-title><source>Immunol Rev</source><year>2011</year><volume>240</volume><issue>1</issue><fpage>105</fpage><lpage>16</lpage><?supplied-pmid 21349089?><pub-id pub-id-type="pmid">21349089</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>TN</given-names></name><name><surname>Hirayama</surname><given-names>K</given-names></name></person-group><article-title>Host genetic susceptibility to severe dengue infection</article-title><source>Trop Med Health</source><year>2011</year><volume>39</volume><issue>4</issue><fpage>73</fpage><lpage>81</lpage><?supplied-pmid 22500139?><pub-id pub-id-type="pmid">22500139</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname><given-names>KB</given-names></name><name><surname>Linthicum</surname><given-names>KJ</given-names></name><name><surname>Myint</surname><given-names>KS</given-names></name><name><surname>Innis</surname><given-names>BL</given-names></name><name><surname>Lerdthusnee</surname><given-names>K</given-names></name><name><surname>Vaughn</surname><given-names>DW</given-names></name></person-group><article-title>Impact of dengue virus infection on feeding behavior of Aedes aegypti</article-title><source>Am J Trop Med Hyg</source><year>1997</year><volume>57</volume><issue>2</issue><fpage>119</fpage><lpage>25</lpage><?supplied-pmid 9288801?><pub-id pub-id-type="pmid">9288801</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>S</given-names></name><name><surname>Ramirez</surname><given-names>JL</given-names></name><name><surname>Dimopoulos</surname><given-names>G</given-names></name></person-group><article-title>Dengue virus infection of the Aedes aegypti salivary gland and chemosensory appara<italic>tus induces</italic> genes that modulate infection and blood-feeding behavior</article-title><source>PLoS Pathog</source><year>2012</year><volume>8</volume><issue>3</issue><fpage>e1002631</fpage><?supplied-pmid 22479185?><pub-id pub-id-type="pmid">22479185</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>WK</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Lin</surname><given-names>YH</given-names></name><name><surname>Hsu</surname><given-names>EL</given-names></name><name><surname>Dai</surname><given-names>SM</given-names></name></person-group><article-title>A novel amino acid substitution in a voltage gated sodium channel is associated with knockdown resistance to permethrin in Aedes aegypti</article-title><source>Insect Biochem Mol Biol</source><year>2009</year><volume>39</volume><issue>4</issue><fpage>272</fpage><lpage>8</lpage><?supplied-pmid 19171193?><pub-id pub-id-type="pmid">19171193</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawada</surname><given-names>H</given-names></name><name><surname>Higa</surname><given-names>Y</given-names></name><name><surname>Komagata</surname><given-names>O</given-names></name><name><surname>Kasai</surname><given-names>S</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Thi Yen</surname><given-names>N</given-names></name><etal/></person-group><article-title>Widespread distribution of newly found point mutation in voltage-gated sodium channel in pyrethroid-resistant Aedes aegypti populations in Vietnam</article-title><source>PLoS Negl Trop Dis</source><year>2009</year><volume>3</volume><issue>10</issue><fpage>e527</fpage><?supplied-pmid 19806205?><pub-id pub-id-type="pmid">19806205</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenhouse</surname><given-names>SA</given-names></name><name><surname>Plernsub</surname><given-names>S</given-names></name><name><surname>Yanola</surname><given-names>J</given-names></name><name><surname>Lumjuan</surname><given-names>N</given-names></name><name><surname>Dantrakool</surname><given-names>A</given-names></name><name><surname>Choochote</surname><given-names>W</given-names></name><etal/></person-group><article-title>Detection of the V1016G mutation in the voltage-gated sodium channel gene of Aedes aegypti (Diptera: Culicidae) by allele-specific PCR assay, and its distribution and effect on deltamethrin resistance in Thailand</article-title><source>Parasit Vectors</source><year>2013</year><volume>6</volume><issue>1</issue><fpage>253</fpage><?supplied-pmid 24059267?><pub-id pub-id-type="pmid">24059267</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De la C Sierra</surname><given-names>B</given-names></name><name><surname>Kour&#x000ed;</surname><given-names>G</given-names></name><name><surname>Guzm&#x000e1;n</surname><given-names>MG</given-names></name></person-group><article-title>Race: A risk factor for dengue hemorrhagic fever</article-title><source>Arch Virol</source><year>2007</year><volume>152</volume><issue>3</issue><fpage>533</fpage><lpage>42</lpage><?supplied-pmid 17106622?><pub-id pub-id-type="pmid">17106622</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a</surname><given-names>G</given-names></name><name><surname>Sierra</surname><given-names>B</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>AB</given-names></name><name><surname>Aguirre</surname><given-names>E</given-names></name><name><surname>Rosado</surname><given-names>I</given-names></name><name><surname>Gonzalez</surname><given-names>N</given-names></name><etal/></person-group><article-title>Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism</article-title><source>Am J Trop Med Hyg</source><year>2010</year><volume>82</volume><issue>6</issue><fpage>1153</fpage><lpage>6</lpage><?supplied-pmid 20519616?><pub-id pub-id-type="pmid">20519616</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakuntabhai</surname><given-names>A</given-names></name><name><surname>Turbpaiboon</surname><given-names>C</given-names></name><name><surname>Casad&#x000e9;mont</surname><given-names>I</given-names></name><name><surname>Chuansumrit</surname><given-names>A</given-names></name><name><surname>Lowhnoo</surname><given-names>T</given-names></name><name><surname>Kajaste-Rudnitski</surname><given-names>A</given-names></name><etal/></person-group><article-title>A variant in the CD209 promoter is associated with severity of the disease</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><issue>5</issue><fpage>507</fpage><lpage>13</lpage><?supplied-pmid 15838506?><pub-id pub-id-type="pmid">15838506</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname><given-names>U</given-names></name><name><surname>Nagar</surname><given-names>R</given-names></name><name><surname>Shrivastava</surname><given-names>R</given-names></name></person-group><article-title>Dengue and dengue haemorrhagic fever: Implications of host genetics</article-title><source>FEMS Immunol Med Microbiol</source><year>2006</year><volume>47</volume><issue>2</issue><fpage>155</fpage><lpage>66</lpage><?supplied-pmid 16831202?><pub-id pub-id-type="pmid">16831202</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soundravally</surname><given-names>R</given-names></name><name><surname>Hoti</surname><given-names>SL</given-names></name></person-group><article-title>Polymorphisms of the TAP 1 and 2 gene may influence clinical outcome of primary dengue viral infection</article-title><source>Scand J Immunol</source><year>2008</year><volume>67</volume><fpage>618</fpage><lpage>625</lpage><?supplied-pmid 18433405?><pub-id pub-id-type="pmid">18433405</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Othman</surname><given-names>S</given-names></name><name><surname>Rahman</surname><given-names>NA</given-names></name><name><surname>Yusof</surname><given-names>R</given-names></name></person-group><article-title>All serotypes of dengue virus induce HLA-A2 major histocompatibility complex class I promoter activity in human liver cells</article-title><source>Trans R Soc Trop Med Hyg</source><year>2010</year><volume>104</volume><issue>12</issue><fpage>806</fpage><lpage>8</lpage><?supplied-pmid 20800252?><pub-id pub-id-type="pmid">20800252</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahram</surname><given-names>S</given-names></name><name><surname>Arnold</surname><given-names>D</given-names></name><name><surname>Bresnahan</surname><given-names>M</given-names></name><name><surname>Strominger</surname><given-names>JL</given-names></name><name><surname>Spies</surname><given-names>T</given-names></name></person-group><article-title>Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region</article-title><source>Proc Natl Acad Sci U S A</source><year>1991</year><volume>88</volume><fpage>10094</fpage><lpage>8</lpage><?supplied-pmid 1946428?><pub-id pub-id-type="pmid">1946428</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alagarasu</surname><given-names>K</given-names></name><name><surname>Honap</surname><given-names>T</given-names></name><name><surname>Damle</surname><given-names>IM</given-names></name><name><surname>Mulay</surname><given-names>AP</given-names></name><name><surname>Shah</surname><given-names>PS</given-names></name><name><surname>Cecilia</surname><given-names>D</given-names></name></person-group><article-title>Polymorphisms in the oligoadenylate synthetase gene cluster and its association with clinical outcomes of dengue virus infection</article-title><source>Infect Genet Evol</source><year>2013</year><volume>14</volume><fpage>390</fpage><lpage>5</lpage><?supplied-pmid 23337612?><pub-id pub-id-type="pmid">23337612</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boonnak</surname><given-names>K</given-names></name><name><surname>Kaitlyn</surname><given-names>MD</given-names></name><name><surname>Gina</surname><given-names>CD</given-names></name><name><surname>Tassaneetrithep</surname><given-names>B</given-names></name><name><surname>Marovich</surname><given-names>AM</given-names></name></person-group><article-title>Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection</article-title><source>J Virol</source><year>2011</year><volume>85</volume><issue>4</issue><fpage>1671</fpage><lpage>1683</lpage><?supplied-pmid 21123382?><pub-id pub-id-type="pmid">21123382</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peurta-Guardo</surname><given-names>H</given-names></name><name><surname>de la Cruz Hernendez</surname><given-names>SI</given-names></name><name><surname>Rosales</surname><given-names>VH</given-names></name><name><surname>Ludert</surname><given-names>JE</given-names></name><name><surname>del Angel</surname><given-names>RM</given-names></name></person-group><article-title>The 1a, 25-dihydroxy-vitamin D3 reduces dengue virus infection in human myelomonocyte (U937) and hepatic (Huh-7) cell lines and cytokine production in the infected monocytes</article-title><source>Antiviral Res</source><year>2012</year><volume>94</volume><issue>1</issue><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">22387385</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alagarasu</surname><given-names>K</given-names></name><name><surname>Honap</surname><given-names>T</given-names></name><name><surname>Mulay</surname><given-names>AP</given-names></name><name><surname>Bachal</surname><given-names>RV</given-names></name><name><surname>Shah</surname><given-names>PS</given-names></name><name><surname>Cecilia</surname><given-names>D</given-names></name></person-group><article-title>Association of vitamin D receptor gene polymorphisms with clinical outcomes of dengue virus infection</article-title><source>Hum Immunol</source><year>2012</year><volume>73</volume><issue>11</issue><fpage>1194</fpage><lpage>9</lpage><?supplied-pmid 22917542?><pub-id pub-id-type="pmid">22917542</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khor</surname><given-names>CC</given-names></name><name><surname>Chau</surname><given-names>TN</given-names></name><name><surname>Pang</surname><given-names>J</given-names></name><name><surname>Davila</surname><given-names>S</given-names></name><name><surname>Long</surname><given-names>HT</given-names></name><name><surname>Ong</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1</article-title><source>Nat Genet</source><year>2011</year><volume>43</volume><issue>11</issue><fpage>1139</fpage><lpage>41</lpage><?supplied-pmid 22001756?><pub-id pub-id-type="pmid">22001756</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinle</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Morris</surname><given-names>DL</given-names></name><name><surname>Groh</surname><given-names>V</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Strong</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family</article-title><source>Immunogenetics</source><year>2001</year><volume>53</volume><fpage>279</fpage><lpage>287</lpage><?supplied-pmid 11491531?><pub-id pub-id-type="pmid">11491531</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, Recher M, et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci USA. 2012;109(4):1210&#x02013;5.</mixed-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitehorn</surname><given-names>J</given-names></name><name><surname>Chau</surname><given-names>TN</given-names></name><name><surname>Nguyet</surname><given-names>NM</given-names></name><name><surname>Kien</surname><given-names>DT</given-names></name><name><surname>Quyen</surname><given-names>NT</given-names></name><name><surname>Trung</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Genetic variants of MICB and PLCE1 and associations with non-severe dengue</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>3</issue><fpage>e59067</fpage><?supplied-pmid 23536857?><pub-id pub-id-type="pmid">23536857</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fink</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Ling</surname><given-names>L</given-names></name><name><surname>Tolfvenstam</surname><given-names>T</given-names></name><name><surname>Olfat</surname><given-names>F</given-names></name><name><surname>Chin</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Host gene expression profiling of dengue virus infection in cell lines and patients</article-title><source>PLoS Negl Trop Dis</source><year>2007</year><volume>1</volume><issue>2</issue><fpage>e86</fpage><?supplied-pmid 18060089?><pub-id pub-id-type="pmid">18060089</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoh</surname><given-names>BP</given-names></name><name><surname>Umi-Shakina</surname><given-names>H</given-names></name><name><surname>Zuraihan</surname><given-names>Z</given-names></name><name><surname>Zaiharina</surname><given-names>MZ</given-names></name><name><surname>Rafidah-Hanim</surname><given-names>S</given-names></name><name><surname>Mahiran</surname><given-names>M</given-names></name><etal/></person-group><article-title>Common variants of chemokine receptor gene CXCR3 and its ligands CXCL10 and CXCL11 associated with vascular permeability of dengue infection in peninsular Malaysia</article-title><source>Hum Immunol</source><year>2015</year><volume>76</volume><issue>6</issue><fpage>421</fpage><lpage>6</lpage><?supplied-pmid 25858769?><pub-id pub-id-type="pmid">25858769</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>NL</given-names></name><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>To</surname><given-names>KF</given-names></name><name><surname>Wu</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome</article-title><source>Clin Chem</source><year>2005</year><volume>51</volume><fpage>2333</fpage><lpage>2340</lpage><?supplied-pmid 16195357?><pub-id pub-id-type="pmid">16195357</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Chan</surname><given-names>YK</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Klein</surname><given-names>RS</given-names></name></person-group><article-title>CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis</article-title><source>J Immunol</source><year>2008</year><volume>180</volume><fpage>2641</fpage><lpage>2649</lpage><?supplied-pmid 18250476?><pub-id pub-id-type="pmid">18250476</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerny</surname><given-names>D</given-names></name><name><surname>Haniffa</surname><given-names>M</given-names></name><name><surname>Shin</surname><given-names>A</given-names></name><name><surname>Bigliardi</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>BK</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><etal/></person-group><article-title>Selective susceptibility of human skin antigen presenting cells to productive dengue virus infection</article-title><source>PLoS Pathog</source><year>2014</year><volume>10</volume><issue>12</issue><fpage>e1004548</fpage><?supplied-pmid 25474532?><pub-id pub-id-type="pmid">25474532</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briant</surname><given-names>L</given-names></name><name><surname>Despr&#x000e8;s</surname><given-names>P</given-names></name><name><surname>Choumet</surname><given-names>V</given-names></name><name><surname>Miss&#x000e9;</surname><given-names>D</given-names></name></person-group><article-title>Role of skin immune cells on the host susceptibility to mosquito-borne viruses</article-title><source>Virology</source><year>2014</year><volume>464&#x02013;465</volume><fpage>26</fpage><lpage>32</lpage><?supplied-pmid 25043586?><pub-id pub-id-type="pmid">25043586</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McArthur</surname><given-names>MA</given-names></name><name><surname>Sztein</surname><given-names>MB</given-names></name><name><surname>Edelman</surname><given-names>R</given-names></name></person-group><article-title>Dengue vaccines: Recent developments, ongoing challenges and current candidates</article-title><source>Expert Rev Vaccines</source><year>2013</year><volume>12</volume><issue>8</issue><fpage>933</fpage><lpage>53</lpage><?supplied-pmid 23984962?><pub-id pub-id-type="pmid">23984962</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hombach</surname><given-names>J</given-names></name></person-group><article-title>Vaccines against dengue: A review of current candidate vaccines at advanced development stages</article-title><source>Rev Panam Salud Publica</source><year>2007</year><volume>21</volume><issue>4</issue><fpage>254</fpage><lpage>260</lpage><?supplied-pmid 17612469?><pub-id pub-id-type="pmid">17612469</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitehead</surname><given-names>SS</given-names></name><name><surname>Blaney</surname><given-names>JE</given-names></name><name><surname>Durbin</surname><given-names>AP</given-names></name><name><surname>Murphy</surname><given-names>BR</given-names></name></person-group><article-title>Prospects for a dengue virus vaccine</article-title><source>Nat Rev Microbiol</source><year>2007</year><volume>5</volume><issue>7</issue><fpage>518</fpage><lpage>528</lpage><?supplied-pmid 17558424?><pub-id pub-id-type="pmid">17558424</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webster</surname><given-names>DP</given-names></name><name><surname>Farrar</surname><given-names>J</given-names></name><name><surname>Rowland-Jones</surname><given-names>S</given-names></name></person-group><article-title>Progress towards a dengue vaccine</article-title><source>Lancet Infect Dis</source><year>2009</year><volume>9</volume><issue>11</issue><fpage>678</fpage><lpage>687</lpage><?supplied-pmid 19850226?><pub-id pub-id-type="pmid">19850226</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raviprakash</surname><given-names>K</given-names></name><name><surname>Defang</surname><given-names>G</given-names></name><name><surname>Burgess</surname><given-names>T</given-names></name><name><surname>Porter</surname><given-names>K</given-names></name></person-group><article-title>Advances in dengue vaccine development</article-title><source>Hum Vaccin</source><year>2009</year><volume>5</volume><issue>8</issue><fpage>520</fpage><lpage>528</lpage><?supplied-pmid 19535912?><pub-id pub-id-type="pmid">19535912</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coller</surname><given-names>BA</given-names></name><name><surname>Clements</surname><given-names>DE</given-names></name></person-group><article-title>Dengue vaccines: Progress and challenges</article-title><source>Curr Opin Immunol</source><year>2011</year><volume>23</volume><issue>3</issue><fpage>391</fpage><lpage>8</lpage><?supplied-pmid 21514129?><pub-id pub-id-type="pmid">21514129</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>B</given-names></name><name><surname>Barrere</surname><given-names>B</given-names></name><name><surname>Malinowski</surname><given-names>C</given-names></name><name><surname>Saville</surname><given-names>M</given-names></name><name><surname>Teyssou</surname><given-names>R</given-names></name><name><surname>Lang</surname><given-names>J</given-names></name></person-group><article-title>From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>42</issue><fpage>7229</fpage><lpage>7241</lpage><?supplied-pmid 21745521?><pub-id pub-id-type="pmid">21745521</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantel</surname><given-names>N</given-names></name><name><surname>Girerd</surname><given-names>Y</given-names></name><name><surname>Geny</surname><given-names>C</given-names></name><name><surname>Bernard</surname><given-names>I</given-names></name><name><surname>Pontvianne</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>38</issue><fpage>6629</fpage><lpage>6635</lpage><?supplied-pmid 21745519?><pub-id pub-id-type="pmid">21745519</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabchareon</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>D</given-names></name><name><surname>Sirivichayakul</surname><given-names>C</given-names></name><name><surname>Limkittikul</surname><given-names>K</given-names></name><name><surname>Chanthavanich</surname><given-names>P</given-names></name><name><surname>Suvannadabba</surname><given-names>S</given-names></name><etal/></person-group><article-title>Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial</article-title><source>Lancet</source><year>2012</year><volume>380</volume><issue>9853</issue><fpage>1559</fpage><lpage>67</lpage><?supplied-pmid 22975340?><pub-id pub-id-type="pmid">22975340</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capeding</surname><given-names>RZ</given-names></name><name><surname>Luna</surname><given-names>IA</given-names></name><name><surname>Bomasang</surname><given-names>E</given-names></name><name><surname>Lupisan</surname><given-names>S</given-names></name><name><surname>Lang</surname><given-names>J</given-names></name><name><surname>Forrat</surname><given-names>R</given-names></name><etal/></person-group><article-title>Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>22</issue><fpage>3863</fpage><lpage>72</lpage><?supplied-pmid 21477675?><pub-id pub-id-type="pmid">21477675</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huu</surname><given-names>TN</given-names></name><name><surname>Quang</surname><given-names>LC</given-names></name><name><surname>Vu</surname><given-names>TQH</given-names></name><name><surname>Forrat</surname><given-names>R</given-names></name><name><surname>Lang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD- TDV) in healthy Vietnamese adults and children</article-title><source>J Vaccines Vaccin</source><year>2012</year><volume>3</volume><fpage>162</fpage></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capeding</surname><given-names>MR</given-names></name><name><surname>Tran</surname><given-names>NH</given-names></name><name><surname>Hadinegoro</surname><given-names>SR</given-names></name><name><surname>Ismail</surname><given-names>HI</given-names></name><name><surname>Chotpitayasunondh</surname><given-names>T</given-names></name><name><surname>Chua</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial</article-title><source>Lancet</source><year>2014</year><volume>384</volume><issue>9951</issue><fpage>1358</fpage><lpage>65</lpage><?supplied-pmid 25018116?><pub-id pub-id-type="pmid">25018116</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villar</surname><given-names>L</given-names></name><name><surname>Dayan</surname><given-names>GH</given-names></name><name><surname>Arredondo-Garc&#x000ed;a</surname><given-names>JL</given-names></name><name><surname>Rivera</surname><given-names>DM</given-names></name><name><surname>Cunha</surname><given-names>R</given-names></name><name><surname>Deseda</surname><given-names>C</given-names></name><etal/></person-group><article-title>CYD15 study group. Efficacy of a tetravalent dengue vaccine in children in Latin America</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>2</issue><fpage>113</fpage><lpage>23</lpage><?supplied-pmid 25365753?><pub-id pub-id-type="pmid">25365753</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Men</surname><given-names>R</given-names></name><name><surname>Bray</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>D</given-names></name><name><surname>Chanock</surname><given-names>RM</given-names></name><name><surname>Lai</surname><given-names>CJ</given-names></name></person-group><article-title>Dengue type 4 virus mutants containing deletions in the 3&#x02019; noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys</article-title><source>J Virol</source><year>1996</year><volume>70</volume><issue>6</issue><fpage>3930</fpage><lpage>7</lpage><?supplied-pmid 8648730?><pub-id pub-id-type="pmid">8648730</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troyer</surname><given-names>JM</given-names></name><name><surname>Hanley</surname><given-names>KA</given-names></name><name><surname>Whitehead</surname><given-names>SS</given-names></name><name><surname>Strickman</surname><given-names>D</given-names></name><name><surname>Karron</surname><given-names>RA</given-names></name><name><surname>Durbin</surname><given-names>AP</given-names></name><etal/></person-group><article-title>A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes</article-title><source>Am J Trop Med Hyg</source><year>2001</year><volume>65</volume><issue>5</issue><fpage>414</fpage><lpage>9</lpage><?supplied-pmid 11716092?><pub-id pub-id-type="pmid">11716092</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durbin</surname><given-names>AP</given-names></name><name><surname>Whitehead</surname><given-names>SS</given-names></name><name><surname>McArthur</surname><given-names>J</given-names></name><name><surname>Perreault</surname><given-names>JR</given-names></name><name><surname>Blaney</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Thumar</surname><given-names>B</given-names></name><etal/></person-group><article-title>rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidates, is safe, immunogenic, and highly infectious in healthy adult volunteers</article-title><source>J Infect Dis</source><year>2005</year><volume>191</volume><issue>5</issue><fpage>710</fpage><lpage>718</lpage><?supplied-pmid 15688284?><pub-id pub-id-type="pmid">15688284</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durbin</surname><given-names>AP</given-names></name><name><surname>McArthur</surname><given-names>J</given-names></name><name><surname>Marron</surname><given-names>JA</given-names></name><name><surname>Blaney</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name><surname>Thumar</surname><given-names>B</given-names></name><name><surname>Wanionek</surname><given-names>K</given-names></name><etal/></person-group><article-title>The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers</article-title><source>Hum Vaccin</source><year>2006</year><volume>2</volume><issue>4</issue><fpage>167</fpage><lpage>173</lpage><?supplied-pmid 17012875?><pub-id pub-id-type="pmid">17012875</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandler</surname><given-names>S</given-names></name><name><surname>Lucas-Hourani</surname><given-names>M</given-names></name><name><surname>Moris</surname><given-names>A</given-names></name><name><surname>Frenkiel</surname><given-names>M-P</given-names></name><name><surname>Combredet</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus</article-title><source>PLoS Negl Trop Dis</source><year>2007</year><volume>1</volume><issue>3</issue><fpage>e96</fpage><?supplied-pmid 18160988?><pub-id pub-id-type="pmid">18160988</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandler</surname><given-names>S</given-names></name><name><surname>Ruffie</surname><given-names>C</given-names></name><name><surname>Najburg</surname><given-names>V</given-names></name><name><surname>Frenkiel</surname><given-names>MP</given-names></name><name><surname>Bedouelle</surname><given-names>H</given-names></name><name><surname>Despr&#x000e8;s</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pediatric measles vaccine expressing a dengue tetravalent antigen elicitsneutralizing antibodies against all four dengue viruses</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><issue>41</issue><fpage>6730</fpage><lpage>9</lpage><?supplied-pmid 20688034?><pub-id pub-id-type="pmid">20688034</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danko</surname><given-names>JR</given-names></name><name><surname>Beckett</surname><given-names>CG</given-names></name><name><surname>Porter</surname><given-names>KR</given-names></name></person-group><article-title>Development of dengue DNA vaccines</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>42</issue><fpage>7261</fpage><lpage>7266</lpage><?supplied-pmid 21777640?><pub-id pub-id-type="pmid">21777640</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckett</surname><given-names>CG</given-names></name><name><surname>Tjaden</surname><given-names>J</given-names></name><name><surname>Burgess</surname><given-names>T</given-names></name><name><surname>Danko</surname><given-names>JR</given-names></name><name><surname>Tamminga</surname><given-names>C</given-names></name><name><surname>Simmons</surname><given-names>M</given-names></name><etal/></person-group><article-title>Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>5</issue><fpage>960</fpage><lpage>968</lpage><?supplied-pmid 21111785?><pub-id pub-id-type="pmid">21111785</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>KR</given-names></name><name><surname>Ewing</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>SJ</given-names></name><name><surname>Hayes</surname><given-names>CG</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><issue>2</issue><fpage>336</fpage><lpage>341</lpage><?supplied-pmid 22085548?><pub-id pub-id-type="pmid">22085548</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>DM</given-names></name><name><surname>de Paula</surname><given-names>SO</given-names></name><name><surname>Fran&#x000e7;a</surname><given-names>RF</given-names></name><name><surname>Palma</surname><given-names>PV</given-names></name><name><surname>Morais</surname><given-names>FR</given-names></name><name><surname>Gomes-Ruiz</surname><given-names>AC</given-names></name><etal/></person-group><article-title>A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>4</issue><fpage>831</fpage><lpage>838</lpage><?supplied-pmid 21115054?><pub-id pub-id-type="pmid">21115054</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>SM</given-names></name><name><surname>Yorio</surname><given-names>AP</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>AJ</given-names></name><name><surname>Vidale</surname><given-names>MM</given-names></name><name><surname>Costa</surname><given-names>EC</given-names></name><name><surname>Mohana-Borges</surname><given-names>R</given-names></name><etal/></person-group><article-title>Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>10</issue><fpage>e25685</fpage><?supplied-pmid 22031819?><pub-id pub-id-type="pmid">22031819</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ming</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>4</issue><fpage>763</fpage><lpage>71</lpage><?supplied-pmid 21095256?><pub-id pub-id-type="pmid">21095256</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putnak</surname><given-names>R</given-names></name><name><surname>Barvir</surname><given-names>DA</given-names></name><name><surname>Burrous</surname><given-names>JM</given-names></name><name><surname>Dubois</surname><given-names>DR</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>VM</given-names></name><name><surname>Hoke</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys</article-title><source>J Infect Dis</source><year>1996</year><volume>174</volume><issue>6</issue><fpage>1176</fpage><lpage>84</lpage><?supplied-pmid 8940206?><pub-id pub-id-type="pmid">8940206</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putnak</surname><given-names>R</given-names></name><name><surname>Barvir</surname><given-names>DA</given-names></name><name><surname>Burrous</surname><given-names>JM</given-names></name><name><surname>Dubois</surname><given-names>DR</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>VM</given-names></name><name><surname>Hoke</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue&#x02013;2 virus vaccine prototype made in fetal rhesus lung cells</article-title><source>Am J Trop Med Hyg</source><year>1996</year><volume>55</volume><issue>5</issue><fpage>504</fpage><lpage>510</lpage><?supplied-pmid 8940981?><pub-id pub-id-type="pmid">8940981</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>AK</given-names></name><name><surname>Putnak</surname><given-names>JR</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Hong</surname><given-names>SP</given-names></name><name><surname>Moon</surname><given-names>SB</given-names></name><name><surname>Barvir</surname><given-names>DA</given-names></name><etal/></person-group><article-title>A purified inactivated Japanese encephalitis virus vaccine made in Vero cells</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><issue>31</issue><fpage>4557</fpage><lpage>4565</lpage><?supplied-pmid 11483284?><pub-id pub-id-type="pmid">11483284</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckels</surname><given-names>KH</given-names></name><name><surname>Putnak</surname><given-names>R</given-names></name></person-group><article-title>Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines</article-title><source>Adv Virus Res</source><year>2003</year><volume>61</volume><fpage>395</fpage><lpage>418</lpage><?supplied-pmid 14714438?><pub-id pub-id-type="pmid">14714438</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaltenb&#x000f6;ck</surname><given-names>A</given-names></name><name><surname>Dubischar-Kastner</surname><given-names>K</given-names></name><name><surname>Eder</surname><given-names>G</given-names></name><name><surname>Jilg</surname><given-names>W</given-names></name><name><surname>Klade</surname><given-names>C</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><issue>33</issue><fpage>4483</fpage><lpage>9</lpage><?supplied-pmid 19486955?><pub-id pub-id-type="pmid">19486955</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Gessel</surname><given-names>Y</given-names></name><name><surname>Klade</surname><given-names>CS</given-names></name><name><surname>Putnak</surname><given-names>R</given-names></name><name><surname>Formica</surname><given-names>A</given-names></name><name><surname>Krasaesub</surname><given-names>S</given-names></name><name><surname>Spruth</surname><given-names>M</given-names></name><etal/></person-group><article-title>Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO) induced neutralizing antibody titers</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>35</issue><fpage>5925</fpage><lpage>31</lpage><?supplied-pmid 21723353?><pub-id pub-id-type="pmid">21723353</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coller</surname><given-names>BA</given-names></name><name><surname>Barrett</surname><given-names>AD</given-names></name><name><surname>Thomas</surname><given-names>SJ</given-names></name></person-group><article-title>The development of Dengue vaccines. Introduction</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>42</issue><fpage>7219</fpage><lpage>7220</lpage><?supplied-pmid 21708208?><pub-id pub-id-type="pmid">21708208</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clements</surname><given-names>DE</given-names></name><name><surname>Coller</surname><given-names>BA</given-names></name><name><surname>Lieberman</surname><given-names>MM</given-names></name><name><surname>Ogata</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Harada</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><issue>15</issue><fpage>2705</fpage><lpage>2715</lpage><?supplied-pmid 20097152?><pub-id pub-id-type="pmid">20097152</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osorio</surname><given-names>JE</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Kinney</surname><given-names>RM</given-names></name><name><surname>Stinchcomb</surname><given-names>DT</given-names></name></person-group><article-title>Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>42</issue><fpage>7251</fpage><lpage>60</lpage><?supplied-pmid 21777638?><pub-id pub-id-type="pmid">21777638</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brewoo</surname><given-names>JN</given-names></name><name><surname>Kinney</surname><given-names>RM</given-names></name><name><surname>Powell</surname><given-names>TD</given-names></name><name><surname>Arguello</surname><given-names>JJ</given-names></name><name><surname>Silengo</surname><given-names>SJ</given-names></name><name><surname>Partidos</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><issue>8</issue><fpage>1513</fpage><lpage>1520</lpage><?supplied-pmid 22178727?><pub-id pub-id-type="pmid">22178727</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durbin</surname><given-names>AP</given-names></name><name><surname>Whitehead</surname><given-names>SS</given-names></name></person-group><article-title>Next-generation dengue vaccines: Novel Strategies currently under development</article-title><source>Viruses</source><year>2011</year><volume>3</volume><issue>10</issue><fpage>1800</fpage><lpage>1814</lpage><?supplied-pmid 22069516?><pub-id pub-id-type="pmid">22069516</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>J</given-names></name><name><surname>Roehrig</surname><given-names>J</given-names></name><name><surname>Barrett</surname><given-names>A</given-names></name><name><surname>Hombach</surname><given-names>J</given-names></name></person-group><article-title>Next generation dengue vaccines: A review of candidates in preclinical development</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>42</issue><fpage>7276</fpage><lpage>84</lpage><?supplied-pmid 21781998?><pub-id pub-id-type="pmid">21781998</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>OK</given-names></name><name><surname>Rodrigo</surname><given-names>WW</given-names></name><name><surname>Quinn</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Rose</surname><given-names>RC</given-names></name><name><surname>Schlesinger</surname><given-names>JJ</given-names></name></person-group><article-title>A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><issue>51</issue><fpage>8085</fpage><lpage>94</lpage><?supplied-pmid 20959154?><pub-id pub-id-type="pmid">20959154</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etemad</surname><given-names>B</given-names></name><name><surname>Batra</surname><given-names>G</given-names></name><name><surname>Raut</surname><given-names>R</given-names></name><name><surname>Dahiya</surname><given-names>S</given-names></name><name><surname>Khanam</surname><given-names>S</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><etal/></person-group><article-title>An envelope domain III&#x02013;based chimeric antigen produced in pichia pastoris elicits Neutralizing antibodies against all four dengue virus serotypes</article-title><source>Am J Trop Med Hyg</source><year>2008</year><volume>79</volume><issue>3</issue><fpage>353</fpage><lpage>363</lpage><?supplied-pmid 18784226?><pub-id pub-id-type="pmid">18784226</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochel</surname><given-names>TJ</given-names></name><name><surname>Raviprakash</surname><given-names>K</given-names></name><name><surname>Hayes</surname><given-names>CG</given-names></name><name><surname>Watts</surname><given-names>DM</given-names></name><name><surname>Russell</surname><given-names>KL</given-names></name><name><surname>Gozalo</surname><given-names>AS</given-names></name><etal/></person-group><article-title>A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in <italic>Aotus</italic> monkeys</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><issue>27</issue><fpage>3166</fpage><lpage>73</lpage><?supplied-pmid 10856796?><pub-id pub-id-type="pmid">10856796</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raviprakash</surname><given-names>K</given-names></name><name><surname>Kochel</surname><given-names>TJ</given-names></name><name><surname>Ewing</surname><given-names>D</given-names></name><name><surname>Simmons</surname><given-names>M</given-names></name><name><surname>Phillips</surname><given-names>I</given-names></name><name><surname>Hayes</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><issue>22</issue><fpage>2426</fpage><lpage>34</lpage><?supplied-pmid 10738100?><pub-id pub-id-type="pmid">10738100</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>M</given-names></name><name><surname>Burgess</surname><given-names>T</given-names></name><name><surname>Lynch</surname><given-names>J</given-names></name><name><surname>Putnak</surname><given-names>R</given-names></name></person-group><article-title>Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy</article-title><source>Virology</source><year>2010</year><volume>396</volume><issue>2</issue><fpage>280</fpage><lpage>288</lpage><?supplied-pmid 19913867?><pub-id pub-id-type="pmid">19913867</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maves</surname><given-names>RC</given-names></name><name><surname>Ore</surname><given-names>RM</given-names></name><name><surname>Porter</surname><given-names>KR</given-names></name><name><surname>Kochel</surname><given-names>TJ</given-names></name></person-group><article-title>Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in <italic>Aotus</italic> nancymaae monkeys</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>15</issue><fpage>2691</fpage><lpage>96</lpage><?supplied-pmid 21303709?><pub-id pub-id-type="pmid">21303709</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gozdek</surname><given-names>A</given-names></name><name><surname>Zhukov</surname><given-names>I</given-names></name><name><surname>Polkowska</surname><given-names>A</given-names></name><name><surname>Poznanski</surname><given-names>J</given-names></name><name><surname>Stankiewicz-Drogon</surname><given-names>A</given-names></name><name><surname>Pawlowicz</surname><given-names>JM</given-names></name><etal/></person-group><article-title>NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: Its mechanism of action and antiviral activity in the replicon system</article-title><source>Antimicrob Agents Chemother</source><year>2008</year><volume>52</volume><issue>2</issue><fpage>393</fpage><lpage>401</lpage><?supplied-pmid 18039921?><pub-id pub-id-type="pmid">18039921</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borowski</surname><given-names>P</given-names></name><name><surname>Heising</surname><given-names>MV</given-names></name><name><surname>Miranda</surname><given-names>IB</given-names></name><name><surname>Liao</surname><given-names>CL</given-names></name><name><surname>Choe</surname><given-names>J</given-names></name><name><surname>Baier</surname><given-names>A</given-names></name></person-group><article-title>ViralNS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI)</article-title><source>Biochem Pharmacol</source><year>2008</year><volume>76</volume><issue>1</issue><fpage>28</fpage><lpage>38</lpage><?supplied-pmid 18479669?><pub-id pub-id-type="pmid">18479669</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>SP</given-names></name><name><surname>Noble</surname><given-names>CG</given-names></name><name><surname>Shi</surname><given-names>PY</given-names></name></person-group><article-title>The dengue virus NS5 protein as a target for drug discovery</article-title><source>Antiviral Res</source><year>2015</year><volume>119</volume><fpage>57</fpage><lpage>67</lpage><?supplied-pmid 25912817?><pub-id pub-id-type="pmid">25912817</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuschl</surname><given-names>T</given-names></name></person-group><article-title>Expanding small RNA interference</article-title><source>Nat Biotechnol</source><year>2002</year><volume>20</volume><issue>5</issue><fpage>446</fpage><lpage>448</lpage><?supplied-pmid 11981553?><pub-id pub-id-type="pmid">11981553</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhoot</surname><given-names>MA</given-names></name><name><surname>Wang</surname><given-names>SM</given-names></name><name><surname>Sekaran</surname><given-names>SD</given-names></name></person-group><article-title>Inhibition of dengue virus entry and multiplication into monocytes using RNA interference</article-title><source>PLoS Negl Trop Dis</source><year>2011</year><volume>5</volume><issue>11</issue><fpage>e1410</fpage><?supplied-pmid 22140591?><pub-id pub-id-type="pmid">22140591</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zandi</surname><given-names>K</given-names></name><name><surname>Teoh</surname><given-names>BT</given-names></name><name><surname>Sam</surname><given-names>SS</given-names></name><name><surname>Wong</surname><given-names>PF</given-names></name><name><surname>Mustafa</surname><given-names>MR</given-names></name><name><surname>Abubakar</surname><given-names>S</given-names></name></person-group><article-title>Antiviral activity of four types of bioflavonoid against dengue virus type-2</article-title><source>Virology J</source><year>2011</year><volume>8</volume><fpage>560</fpage><pub-id pub-id-type="pmid">22201648</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talarico</surname><given-names>LB</given-names></name><name><surname>Pujol</surname><given-names>CA</given-names></name><name><surname>Zibetti</surname><given-names>RG</given-names></name><name><surname>Far&#x000ed;a</surname><given-names>PC</given-names></name><name><surname>Noseda</surname><given-names>MD</given-names></name><name><surname>Duarte</surname><given-names>ME</given-names></name><etal/></person-group><article-title>The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell</article-title><source>Antiviral Res</source><year>2005</year><volume>66</volume><issue>2&#x02013;3</issue><fpage>103</fpage><lpage>110</lpage><?supplied-pmid 15911027?><pub-id pub-id-type="pmid">15911027</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>LI</given-names></name><name><surname>Ling</surname><given-names>AP</given-names></name><name><surname>Koh</surname><given-names>RY</given-names></name><name><surname>Chye</surname><given-names>SM</given-names></name><name><surname>Voon</surname><given-names>KG</given-names></name></person-group><article-title>Screening of anti-dengue activity in methanolic extracts of medicinal plants</article-title><source>BMC Complement Altern Med</source><year>2012</year><volume>12</volume><fpage>3</fpage><?supplied-pmid 22244370?><pub-id pub-id-type="pmid">22244370</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>TP</given-names></name></person-group><article-title>Dengue: The risk to developed and developing countries</article-title><source>Proc Natl Acad Sci U S A</source><year>1994</year><volume>91</volume><issue>7</issue><fpage>2395</fpage><lpage>400</lpage><?supplied-pmid 8146129?><pub-id pub-id-type="pmid">8146129</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>P</given-names></name><name><surname>Ricci</surname><given-names>I</given-names></name><name><surname>Cappelli</surname><given-names>A</given-names></name><name><surname>Damiani</surname><given-names>C</given-names></name><name><surname>Ulissi</surname><given-names>U</given-names></name><name><surname>Mancini</surname><given-names>MV</given-names></name><etal/></person-group><article-title>Mutual exclusion of Asaia and Wolbachia in the reproductive organs of mosquito vectors</article-title><source>Parasit Vectors</source><year>2015</year><volume>8</volume><fpage>278</fpage><?supplied-pmid 25981386?><pub-id pub-id-type="pmid">25981386</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><mixed-citation publication-type="other">Mendes H: Brazil tests GM mosquitoes to fight Dengue. Males with offspring-killing genes are replacing wild insects, say researchers. 11 April 2012. <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/news/brazil-tests-gm-mosquitoes-to-fight-dengue-1.10426">http://www.nature.com/news/brazil-tests-gm-mosquitoes-to-fight-dengue-1.10426</ext-link>.</mixed-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>AA</given-names></name><name><surname>Montgomery</surname><given-names>BL</given-names></name><name><surname>Popovici</surname><given-names>J</given-names></name><name><surname>Iturbe-Ormaetxe</surname><given-names>I</given-names></name><name><surname>Johnson</surname><given-names>PH</given-names></name><name><surname>Muzzi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission</article-title><source>Nature</source><year>2011</year><volume>476</volume><issue>7361</issue><fpage>454</fpage><lpage>7</lpage><?supplied-pmid 21866160?><pub-id pub-id-type="pmid">21866160</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNaughton</surname><given-names>D</given-names></name><name><surname>Duong</surname><given-names>TT</given-names></name></person-group><article-title>Designing a community engagement framework for a new dengue control method: a case study from central Vietnam</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>8</volume><issue>5</issue><fpage>e2794</fpage><?supplied-pmid 24853391?><pub-id pub-id-type="pmid">24853391</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alen</surname><given-names>MM</given-names></name><name><surname>Schols</surname><given-names>D</given-names></name></person-group><article-title>Dengue virus entry as target for antiviral therapy</article-title><source>J Trop Med</source><year>2012</year><volume>2012</volume><fpage>628475</fpage><?supplied-pmid 22529868?><pub-id pub-id-type="pmid">22529868</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>CO</given-names></name><name><surname>Costin</surname><given-names>JM</given-names></name><name><surname>Rowe</surname><given-names>DK</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Jenwitheesuk</surname><given-names>E</given-names></name><name><surname>Samudrala</surname><given-names>R</given-names></name><etal/></person-group><article-title>Viral entry inhibitors block dengue antibody-dependent enhancement in vitro</article-title><source>Antiviral Res</source><year>2011</year><volume>89</volume><issue>1</issue><fpage>71</fpage><lpage>74</lpage><?supplied-pmid 21093488?><pub-id pub-id-type="pmid">21093488</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Courageot</surname><given-names>MP</given-names></name><name><surname>Frenkiel</surname><given-names>MP</given-names></name><name><surname>Duarte dos Santos</surname><given-names>CN</given-names></name><name><surname>Deubel</surname><given-names>V</given-names></name><name><surname>Despr&#x000e8;s</surname><given-names>P</given-names></name></person-group><article-title>&#x003b1;-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum</article-title><source>J Virol</source><year>2000</year><volume>74</volume><fpage>564</fpage><lpage>572</lpage><?supplied-pmid 10590151?><pub-id pub-id-type="pmid">10590151</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitby</surname><given-names>K</given-names></name><name><surname>Pierson</surname><given-names>TC</given-names></name><name><surname>Geiss</surname><given-names>B</given-names></name><name><surname>Lane</surname><given-names>K</given-names></name><name><surname>Engle</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo</article-title><source>J Virol</source><year>2005</year><volume>79</volume><issue>14</issue><fpage>8698</fpage><lpage>8706</lpage><?supplied-pmid 15994763?><pub-id pub-id-type="pmid">15994763</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alen</surname><given-names>MM</given-names></name><name><surname>Kaptein</surname><given-names>SJ</given-names></name><name><surname>De Burghgraeve</surname><given-names>T</given-names></name><name><surname>Balzarini</surname><given-names>J</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Schols</surname><given-names>D</given-names></name></person-group><article-title>Antiviral activity of carbohydrate binding agents and the role of DC-SIGN in dengue virus infection</article-title><source>Virology</source><year>2009</year><volume>387</volume><issue>1</issue><fpage>67</fpage><lpage>75</lpage><?supplied-pmid 19264337?><pub-id pub-id-type="pmid">19264337</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Pavy</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>N</given-names></name><name><surname>Freeman</surname><given-names>C</given-names></name><name><surname>Lobigs</surname><given-names>M</given-names></name></person-group><article-title>Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic Flaviviruses</article-title><source>Antiviral Res</source><year>2006</year><volume>69</volume><issue>1</issue><fpage>31</fpage><lpage>38</lpage><?supplied-pmid 16309754?><pub-id pub-id-type="pmid">16309754</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidari</surname><given-names>KI</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Arihara</surname><given-names>M</given-names></name><name><surname>Nagaoka</surname><given-names>M</given-names></name><name><surname>Morita</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name></person-group><article-title>Structure and anti-dengue virus activity of sulfated polysaccharide from a marine alga</article-title><source>Biochem Biophysic Res Comm</source><year>2008</year><volume>376</volume><issue>1</issue><fpage>91</fpage><lpage>5</lpage></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>K</given-names></name><name><surname>Zuo</surname><given-names>J</given-names></name></person-group><article-title>Structure elucidation and sulfated derivatives preparation of two <italic>&#x003b1;</italic>-dglucans from <italic>Gastrodia elata</italic> Bl. and their anti-dengue virus bioactivities</article-title><source>Carbohydr Res</source><year>2007</year><volume>342</volume><issue>15</issue><fpage>2230</fpage><lpage>2236</lpage><?supplied-pmid 17637459?><pub-id pub-id-type="pmid">17637459</pub-id></element-citation></ref></ref-list></back></article>